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Abstract 
Streptococcus iniae causes severe septicemia and meningitis in farmed fish and is also 
occasionally zoonotic. Vaccination against S. iniae is problematic, with frequent 
breakdown of protection in vaccinated fish. The major protective antigens in S. iniae are 
the polysaccharides of the capsule, which are essential for virulence. Capsular 
biosynthesis is driven and regulated by a 21-kb operon comprising up to 20 genes. In a 
long-term study, we have sequenced the capsular operon of strains that have been used 
in autogenous vaccines across Australia and compared it with the capsular operon 
sequences of strains subsequently isolated from infected vaccinated fish. Intriguingly, 
strains isolated from vaccinated fish that subsequently become infected have coding 
mutations that are confined to a limited number of genes in the CPS (capsular 
polysaccharide) operon, with the remainder of the genes in the operon remaining stable. 
Mutations in strains in diseased vaccinated fish occur in key genes in the capsular operon 
that are associated with polysaccharide configuration (cpsG) and with regulation of 
biosynthesis (cpsD and cpsE). This, along with high ratios of non-synonymous to 
synonymous mutations within the CPS genes, suggests that immune response directed 
predominantly against capsular polysaccharide may be driving evolution in a very specific 
set of genes in the operon. From these data, it may be possible to design a simple 
polyvalent vaccine with a greater operational life span than the current monovalent killed 
bacterins. 
I investigated antigenic effects of a key CPS biosynthesis gene, cpsG, a putative UDP-
galactose 4-epimerase that has three sequence types based on the insertion or deletion of 
the three amino acids leucine, serine and lysine in the substrate binding site of the protein. 
To elucidate the role of cpsG in CPS biosynthesis and capsular composition, I first 
prepared isogenic knockout and complemented mutants of cpsG by allelic exchange 
mutagenesis. Deletion of cpsG resulted in changes to colony morphology and cell buoyant 
density, and also significantly decreased galactose content relative to glucose in the 
capsular polysaccharide as determined by GC-MS, consistent with epimerase activity of 
cpsG. There was also a metabolic penalty of cpsG knockout revealed by slower growth in 
complex media, and reduced proliferation in whole fish blood. Moreover, whilst antibodies 
raised in fish against the wild type cross-reacted in whole cell and cps ELISA, they did not 
cross-opsonise the mutant in a peripheral blood neutrophil opsonisation assay, consistent 
with reported vaccine escape. We have shown here that mutation in cpsG results in 
altered CPS composition and this in turn results in poor cross-opsonisation that explains 
some of the historic vaccination failure on fish farms in Australia. 
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“When we try to pick out anything by itself, we find it hitched to everything 
else in the Universe.” 
- John Muir 
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1 Introduction  
 
Foreign microbes in contact with the hosts immune system are subject to defence 
mechanisms that are equipped to neutralise them.  Adaptive or acquired recognition 
occurs via antibody responses to surface molecules or antigens on a foreign invader such 
as a pathogen.  Pathogens are microorganisms that cause infection within the host, and 
may include resident bacteria if homeostasis is disturbed (1).  Antigens on pathogenic 
bacteria are composed of proteins and/or carbohydrates (2), and can be found in the cell 
wall, capsule, and intercellular slime/mucous on bacteria.  Numerous variations in antigen 
structure and composition allow the bacterium to evade host defences (2). Evolution to 
avoid the host’s immune response is the driving force for antigenic variation and ultimately 
results in improved fitness of the bacterium in the immune host.  This evolutionary process 
has been tracked during vaccine programs, with new strains re-emerging that are 
antigenically different to previous strains (3-5).  The most striking examples of antigenic 
variation include Streptococcus pneumoniae, with over 90 different serotypes occurring (4, 
6), and influenza virus, that is constantly changing in response to vaccine selection 
pressure (7).   
Vaccination remains the most effective tool in the global fight against infectious diseases, 
yet each year new pandemics  arise as new serotypes emerge, evidenced by 
antigenic variation of influenza virus in response to flu vaccine selection pressure (7).  
Every year, flu vaccines are reformulated to target the main circulating viruses (determined 
by world-wide surveillance) and their highly mutable antigenic structures (8).  Vaccine 
efficacy is dependent on matching the antigenic structures of the influenza strains that are 
circulating through the population. In most cases, the vaccine matches adequately 
affording 70-90% reduced influenza cases, but may only be 40-60% effective when it 
matches less well (9).  
Vaccines against bacterial pathogens are also subject to selective pressure of the host 
immune system. For example S. pneumoniae strains use molecular camouflage to avoid 
immune attack that is primed through vaccination (10-12).   This camouflage may be 
achieved, in part, by changing the polysaccharide capsule (CPS) external to the bacterial 
cell wall. The CPS encapsulates bacteria, is highly antigenic, and the structure varies 
among not only bacterial species, but also between strains within a species (13).  
Targeting various CPS structures and trying to anticipate selective pressure from the host 
induced by vaccines has proven difficult (14, 15).  Formulating vaccines has been 
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traditionally based on identifying proteins that elicit an immune response, purifying these, 
and testing using model organisms (8, 16).  More recently, reverse vaccinology has been 
employed to identify a suite of potential vaccine candidates (17).  Reverse vaccinology 
may hold the key to designing appropriate vaccines based on virulence factors identified in 
whole genome sequences. Since there are various factors at play in causing infection, a 
vaccine that targets multiple virulence determinants is ideal (18).  At the same time, 
understanding the molecular mechanisms of the virulence determinants and how the host 
is responding is equally important.  
1.1 Objective 
Streptococcus iniae, a zoonotic bacterium, expresses several virulence determinants, with 
the CPS being most immune-dominant (19).  A common aquatic pathogen, S. iniae is 
vaccinated against on aquaculture farms to prevent future outbreaks.   However, like flu 
shots, these vaccines are only effective for a short time as the bacteria evolves and re-
emerges (20).  In order to develop effective vaccines, we therefore need to know how S. 
iniae is changing in response to vaccines and how these changes affect the antigenicity of 
this pathogen. 
1.2 Aims 
The aim of this project is to address one central question: how do specific mutations in the 
capsular operon of re-emergent strains of S. iniae affect antigenicity? 
Specific aims: 
1) Identify re-emerging strains of S. iniae and determine genetic effects using large scale 
screening of capsular genes 
2). Use allelic replacement to knockout genes in the capsular operon of S. iniae, and 
elucidate phenotypes with a defined genetic background 
3) Raise antibodies in barramundi and use ELISA and killing assays to determine 
antigenic properties with mutant strains 
1.3 Study Setting 
The work for this thesis was focused on re-emerging strains of S. iniae from barramundi 
(Lates calcarifer) aquaculture farms in Australia.  Barramundi farms in Australia are unique 
in that they have a closed cycle for monitoring vaccine driven evolution by using 
autogenous vaccines.  Strains from re-emerging infections with S. iniae were stored 
accordingly and analysed. 
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1.4 Overview of Thesis Chapters 
Chapter 1 includes a concise literature review and background highlighting the need for 
antigenic studies in S. iniae.  
Chapter 2 is the foundation for the thesis and its subsequent studies.  It’s the first time a 
large-scale genetic screen was performed on re-emerging S. iniae isolates in Australia. 
Specific biosynthesis genes were found to possess mutations, and were the target for 
further investigation into capsular antigenicity.   
Chapter 3 looks at the first biosynthesis gene of interest cpsG, putatively an UDP-glucose 
4’-epimerase.  Amino acid mutations identified in cpsG are unique from the large screen 
found in chapter 2.  In one strain an amino acid insertion of LSK (leucine, serine, lysine) 
and in another strain in the same location, a deletion of the same amino acid sequence.  
The strains were vigorously tested for enzyme activities, blood killing ability, and ultimately 
allelic replacement for total effect of the gene in the capsular operon. 
Chapter 4 discusses conclusions and findings from Chapter 2 & 3. 
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1.5 Literature Review 
1.6 Aquaculture 
For centuries, humans have fished for food and this industry provides a major source of 
high quality protein throughout the world.  As a consequence, many regions have 
witnessed over fishing of desirable food species coupled with a lack of timely stock 
recovery (21).  A more sustainable answer has been the rapid growth of aquaculture, 
where aquatic organisms including plants, shellfish and fish, are farmed and sold to local, 
national, and international markets. Over the last few decades, aquaculture has expanded 
to farm fish that are typically exploited from overfishing, increasing production from 9% of 
total food fish in the 80s to 43% of total fish for food use in 2012 (22).   
There are several types of facilities for farming aquatic species, with the main goal being a 
product that is sustainable and profitable. Farm facilities are designed to mimic the natural 
habitat of the marine organism being cultivated (open ocean cages, ponds, coastal cages), 
however, with advances in technology, indoor re-circulating systems have become the 
preferred method with low environmental impact and very high potential yields (23).  
Indoor re-circulation systems work by passing water through filters where bacteria are 
used to breakdown the by-products formed by the organisms being farmed (23).   
Although expensive, this method allows more control in an otherwise highly variable 
setting. Outdoor ponds are less expensive and widely used, but are susceptible to 
environmental and anthropogenic factors that make it difficult to control infections (24).  
For these reasons, optimal animal husbandry is critical as well as water quality 
management to ward off infections. 
1.6.1 Aquaculture infections and treatment options 
As aquaculture became increasingly intensified, infections were more prevalent as fish 
were stocked at higher densities, enabling rapid proliferation and transmission between 
individuals. In the 1980’s and 1990’s, Norway’s salmonid industry was devastated by 
Vibrio and Aeromonas salmonicida infections (25).  
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This initially led to a surge in antibiotic use to control infections during the 1980’s, but this 
strategy was replaced in the mid-1990’s with vaccines, as antibiotic use in major 
aquaculture species had been severely compromised due to the rise in antibiotic 
resistance (25). There are three ways to administer vaccines: immersion, intra-peritoneal 
injection, and orally (26).  Immersion vaccines are used in small fish but elicit a relatively 
short duration of immunity while oral vaccines have had little success in a practical farm 
environment due to difficulties with protecting high antigen doses through the gut (16).  
Intraperitoneal injections are frequently used as a mode for delivering vaccines because 
this elicits a high circulating antibody response. Although intraperitoneal injections are 
labour intensive they are the most commonly used form of vaccination in fish due to their 
high efficacy and long duration of immunity (26, 27). Intraperitoneal vaccines are usually 
comprised of formalin-inactivated bacteria, although occasionally live attenuated bacteria 
and recombinant proteins have been applied (22, 26, 27).   
In Australian aquaculture producers have to approach infection prevention/treatment 
differently as there are few licenses for commercial vaccines. Aquaculture in Australia 
began in the 1960’s, and is the fastest growing production sector in Australia (28). One of 
the more successful farmed fish species is barramundi (Lates calcarifer), grossing thirty 
million dollars annually in Australia (29).  However, since 1992, infections caused by S. 
iniae in farmed barramundi (30) have caused serious problems for fish farmers, and thus 
treatment options have been intensively researched.  Treatment with antibiotics such as 
penicillin, erythromycin, and carbenicillin were trialled in the Amazon river dolphin as an 
inexpensive way to treat S. iniae infection, but it was still inefficient as some treatment 
cycles take over 18 months (31). Autogenous vaccination is most often used on Australian 
barramundi farms to prevent S. iniae infection. Autogenous vaccines must be comprised of 
strains that are initially isolated from the farm where the infection occurred.  Strains are 
documented through the state veterinary laboratories and then provided to a registered 
manufacturer to produce a custom vaccine, which may then be used to vaccinate stock for 
introduction onto the original farm (5).  Autogenous vaccines (delivered via intraperitoneal 
injection) generally work well however, occasionally re-emerging strains occur in 
previously vaccinated stock due to high variability in the capsular polysaccharide (CPS) 
structure, the major antigenic determinant in S. iniae. This was first reported in rainbow 
trout in Israel, and latterly in Australian barramundi (19, 20). This poses a significant 
problem for development of effective vaccines against highly variable pathogens that are 
increasingly occurring in the growing finfish aquaculture industry.  
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1.7 Streptococcus iniae   a global pathogen 
S. iniae is ubiquitous in warm and temperate waters, infecting wild and farmed fish 
including tilapia, rainbow trout, and barramundi (5). Gram positive and beta-haemolytic, S. 
iniae forms cocci chains, like other streptococci, and generally displays small translucent 
colony morphology (5).  S. iniae was originally isolated from an Amazon freshwater 
dolphin in 1976 (32), and has a wide host range, including humans (5).  There is no 
definitive serotyping scheme for S. iniae although several reports of differing serotype 
exist:  Serotype I, considered classical , was reported to result in less severe 
pathogenesis compared with some other serotypes (33). Infection with “serotype I in 
fish, results in lesions on the skin and rarely meningitis.  “Serotype II” differed 
biochemically from “serotype I” being arginine dihydrolase and ribose positive, and was 
identified after a vaccine program in Israel (34).  Pathogenesis includes damage to 
different organs, crossing of the blood brain barrier, and S. iniae has also been found in 
the bone of the fish host (20, 33, 34). Infections in humans can occur when an open 
wound is infected with S. iniae during the handling or processing of infected fish (5). 
Symptoms can range from bacteraemic cellulitis, arthritis, toxic shock and sepsis (35). 
These symptoms are exacerbated in immunocompromised individuals, and are often hard 
to treat as the bacteria enter the bloodstream (36).   
In fish, S. iniae causes skin lesions, exophthalmia or eye bulging (usually bilateral), 
meningitis, and in most cases leads to death (35).  Again, severe infections occur in fish 
when the immune system is compromised.  Fish become immunocompromised due to 
fighting with other fish (which stresses individual fish), inadequate water quality conditions, 
or poor fish husbandry (5). Transmission of S. iniae in fish is not well understood, but in 
marine caged fish is thought to occur via an oral-faecal route or by ingesting carrier fish 
(37, 38).  While most infections of S. iniae in Australia occur in pond aquaculture, the 
environmental source of the pathogen remains unknown (38).  Understanding how S. iniae 
is transmitted, and more importantly where the bacterium comes from, is critical for 
vaccine design, infection control, and evolution of re-emerging strains. 
1.7.1 S. iniae virulence factors 
 
Progress has been made in the identification of factors that contribute to S. iniae virulence 
(10, 19, 35, 39, 40).  Genomic studies have shown homology to Streptococcus pyogenes 
genes found including M-like protein (simA), C5a peptidase (scpl), and genes of the sag 
operon that contribute to SLS production (41, 42).  Mutation of the genes encoding these 
proteins resulted in attenuation of S. iniae virulence, as well as changes to pathology at 
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the site of infection (41, 42).  In light of these findings that M-like protein contributes to 
virulence, a vaccination and challenge experiment was designed in barramundi (Lates 
calcarifer) using M-like protein (SiMA). However, the vaccine did not protect against 
challenge strains (43)  Other virulence determinants have been identified on the surface of 
S. iniae (Fig. 1), and some have subsequently been tested as vaccine candidates (44).   
Unfortunately, none of these experimental vaccines is able to elicit cross protection, 
reinforcing the view that that the CPS is the major antigenic determinant (35, 43). 
 
 
Fig. 1 Streptococcus iniae virulence factors that may protrude through the polysaccharide 
capsule, or are secreted (Baiano & Barnes 2009). Abbreviations: C5a = complement 
component 5a, IL-8 = interleukin 8, L=Lymphocytes, E= Erythrocytes, N= Neutrophils, 
SLS= Streptolysin S, Ig= Immunoglobulin, CAMP= Christie, Atkins, and Munch-Peterson), 
EPS= extracellular polysaccharides, CPS= capsular polysaccharide, SiM= Streptococcus 
iniae M-like protein. 
In spite of this progress, the majority of vaccines against S. iniae are still simple formalin 
inactivated cultures that result in the immune system substantially targeting the 
polysaccharide capsule. The identification of the capsular operon in S. iniae was a 
significant finding, and by using molecular techniques, has advanced understanding of 
both virulence and immune evasion.  For now, the hurdle remains to find a suitable 
vaccine that will provide cross protection and not give rise to new emerging strains. 	
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1.8 Vaccine escape and the polysaccharide capsular operon 
 
1.8.1 Evolution of new serotypes 
Several studies have shown pathogens have the ability to re-emerge after vaccine 
programs (45-48).  In the 1980s vaccines were initiated for infectious bursal disease 
(IBD) in chickens, which causes respiratory infections and contributes to economic loss 
globally (47).  Antigenically distinct strains started emerging in the U.S., and across 
Europe, with highly virulent strains dominating the population and mortality rates at greater 
than 60 % (49).  Similarly, avian influenza, widespread amongst commercial poultry, has 
faced difficulty with strains re-emerging after vaccination programs that targeted specific 
antigenic determinants (50).  Animals are not the only species affected by re-emerging 
strains, human pathogenic strains have also evolved due to clinical intervention.  During 
the 80s a vaccine containing specific recombinant surface antigens was designed for 
patients with Hepatitis B (51).  Mutations were found in subsequent strains with amino acid 
modifications to specific surface antigens (48).  These studies all share a common issue of 
epitope escape mutants, or serotypes that arise in a population displaying differences in 
antigen presentation. Most vaccines against pathogens are designed to target protective 
antigens or epitopes that are highly immunogenic, as such they are usually the most 
variable (52).  In anticipation of epitope variation, vaccines are often designed with multiple 
recombinant antigens, as in the case with Hepatitis B amongst others, that are known to 
illicit an immune response (51).  This design leaves an opening for non-vaccine strains to 
gain, overtime, components not present in the vaccine to elude the immune system (47).  
Alterations to epitopes are not the only type of vaccine driven evolution, virulence 
adaptations have also been described (15).  Virulence adaptations can occur when 
vaccines are designed to reduce pathogen growth, toxicity effects, and transmission (15).  
More specifically, how virulence interacts with vaccinated and un-vaccinated hosts over 
time.  This type of vaccine driven evolution has attracted attention recently, as Read and 
colleagues were able to show that vaccinations with  leaky vaccines  (where 
transmission is not terminated) against Mareks disease virus (MDV) in commercial 
chickens led to unvaccinated chicken infections and ultimately hyperpathogenic strains of 
MDV (55).  It is important to distinguish between these types of vaccine driven evolution 
and how serotypes can arise in a population however, the focus here will remain on 
epitope variation driven by vaccination in streptococcal infections.   
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1.8.2 Streptococcal infections and re-emerging strains 
There are several different streptococcal species that infect a wide variety of hosts (5, 12, 
37, 56, 57). Many streptococci also live commensally, only causing infection in 
immunocompromised individuals. These include Streptococcus pyogenes, more 
commonly referred to as strep throat, and Streptococcus agalactiae (GBS), that may 
live commensally within a percentage of the population, occasionally causing overt 
infectious disease (12, 57).  In spite of the diversity in host range, and modes of 
infection/colonisation, there are several similarities among streptococcal virulence factors 
that allow them to evade host defences, the most ubiquitous being the capsule (11, 19, 
58).  Vaccine programs using purified CPS have shown promise for short-term infections, 
however, several re-emerging cases have been reported with evidence of epitope 
variation (45, 59).  S. pneumoniae, well known for infecting humans globally, possesses 
over 90 capsular serotypes (47).  Re-emerging strains were identified after clinical trials 
during the 1990s, where vaccines were composed of multiple capsular serotypes. These 
types of changes to the CPS have also been documented in GBS after vaccine programs 
(59).  Surprisingly, a capsular shift occurred in a usually homogenous GBS strain due to 
an exchange of a DNA fragment in the cps operon, subjecting the vaccine target to 
variation (59).  One of the first cases of a re-emerging S. iniae strain was in Israel after a 
vaccination program, and subsequently S. iniae strains were identified after vaccination 
programs in Australia (3, 20).  The Israeli vaccine program was performed on rainbow trout 
(Oncorhynchus mykiss), and re-emerging strains of S. iniae had evolved to produce 
excessive amounts of highly antigenic EPS (extracellular polysaccharide) (3).  This led to 
increased virulence and enhanced the ability of the pathogen to escape the immune 
system and establish infection.  Re-emerging strains of S. iniae identified in Australia were 
found in barramundi (Lates calcarifer), on several different fish farms with vaccine 
programs.  In some of the re-emerging Australian S. iniae strains, the CPS was not 
present and a new, unusual pathology was present in fish (20). These strains were found 
to infect the bone of fish, causing severe spinal deformities but low mortality.  Where as 
other re-emerging strains were infecting the previously vaccinated fish, but the CPS 
yielded differences in amino acid sequence when compared to the WT strain.  Sequencing 
of the CPS operon from all re-emerging strains in Australian fish farms revealed that 
vaccination was driving mutation of key genes involved in polysaccharide biosynthesis and 
transport. SNPs and truncated genes were identified in the CPS operon, contributing to 
re-infection and the unusual pathology that was observed with the loss of capsule (20). 	
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1.8.3 CPS operon 
The polysaccharide capsule of S. iniae is similar to the CPS found in other virulent 
streptococcal groups and bacterial species in general (11, 13, 60). The CPS is covalently 
bound to the surface of the bacterial cell, composed of monosaccharides, and may contain 
several configurations depending on the number of hydroxyl groups present (19, 61). The 
capsular operon encodes the machinery that synthesises, exports and anchors the 
polysaccharide to the cell.  Clustering of CPS genes is a common feature among most 
bacterial species, spanning a range from 10  20 kb in length (62).  Genes within the 21-kb 
capsular operon of S. iniae (Fig 2.) were identified in 2007 (19), and genes of interest were 
identified as those that are putatively responsible for initiating polysaccharide biosynthesis 
(cpsY, and cpsD-cpsH), which are conserved among several streptococcal species (36). 
Using allelic replacement, mutation of the gene encoding an auto-phosphorylating protein 
tyrosine kinase, cpsD, resulted in diminished phagocytic function due to a lack of capsule 
production (10).  cpsY, a transcriptional regulator, was found to contribute to protection of 
S. iniae against neutrophil killing and regulate growth in vitro (63).  Two other genes that 
are implicated in capsule biosynthesis that have not been previously investigated are 
cpsE, a putative glucose dependent glycosyltransferase and cpsG, a putative UDP-
glucose-4’epimerase.  Glycosyltransferases build monosaccharide moieties that form 
branched or linear glycan chains (64).  Antigenic variation in the glycoslytransferase 
operon of Salmonella enterica subspecies Typhimurium, showed an increase in sugars on 
the O-antigen structure ultimately changing the serotype (65).  UDP-glucose 4 -
epimerases control the ratio of glucose:galactose as part of the last step in the Leloir 
pathway for galactose metabolism, and is found in all three branches of life (66, 67).  
Mutations of this gene are known to cause galactosemia in children and affect their ability 
to metabolise Leloir products (68).  These genes play an important role in various species 
reinforcing the need to study them in S. iniae.  Polysaccharide biosynthesis genes play a 
critical role in the final capsular product, determining CPS antigenicity, and how the 
bacterium eludes its host (5, 36, 63). 
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Fig. 2 Genes and their orientation in the 21kb capsular operon of the S. iniae type strain 
(140). (Figure modified from Lowe et al., 2007)       
  
Although molecular differences exist between bacterial species, the capsule is required for 
successful infection by many systemic pathogens.  Intriguingly, type III group B 
Streptococcus (GBS) species have a different chemical composition in their capsule via 
sialic acid residues, thus preventing complement C3 deposition on the bacterial cell (58).  
Adaptation and evolution of pathogens reveals the ability to alter their capsules and 
prevent immune detection (3, 40).   
Studies on the composition and chemical configuration of S. iniae CPS are lacking, but we 
know the CPS is a complex matrix of neutral and charged sugars (10, 39).  Polysaccharide 
capsules mask the pathogen allowing them to successfully by-pass the first line of defence 
and disseminate through the host. Without the capsule, the immune system has a better 
chance of recognising surface structures and eliminating the pathogen (11, 36).  
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Abstract 
Streptococcus iniae causes severe septicaemia and meningitis in farmed fish and is also 
occasionally zoonotic. Vaccination against S. iniae is problematic with frequent breakdown 
of protection in vaccinated fish. The major protective antigens in S. iniae are the 
polysaccharides of the capsule, which are essential for virulence. Capsular biosynthesis is 
driven and regulated by a 21 kb operon comprising up to 20 genes. In a long-term study, 
we have sequenced the capsular operon of strains that have been used in autogenous 
vaccines across Australia and compared them with the capsular operon sequences of 
strains subsequently isolated from infected vaccinated fish. Intriguingly, strains isolated 
from vaccinated fish that subsequently become infected have coding mutations that are 
confined to a limited number of genes in the cps operon with the remainder of the genes in 
the operon remaining stable. Mutations in strains in diseased vaccinated fish occur in key 
genes in the capsular operon associated with polysaccharide configuration (cpsG) and 
with regulation of biosynthesis (cpsD and cpsE). This, along with high ratios of non-
synonymous to synonymous mutations within the cps genes suggests that immune 
response directed predominantly against capsular polysaccharide may be driving evolution 
in a very specific set of genes in the operon. From these data it may be possible to design 
a simple polyvalent vaccine with a greater operational lifespan than the current 
monovalent killed bacterins. 
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2.1 Introduction 
Evasion of the adaptive immune response through genetic evolution of a pathogen is a 
major factor governing long-term vaccine success (15). This is dependent on the nature of 
the antigens targeted by the adaptive immune response: If they are highly conserved, the 
diversity among the population will be low, or the population may be eliminated altogether 
with re-emergence of disease in vaccinated stock rarely occurring (15, 16). In contrast, 
adaptive immune selection against highly polymorphic antigenic determinants may result 
in pathogen populations restructuring into antigenic types or serotypes, with certain types 
predominating in vaccinated stock and fluctuations in the genetic structure of the 
population dictated by the serotype or types included in the vaccine (15).  
Vaccinations against Streptococcus iniae infections in barramundi farms in Australia 
provide an ideal model for exploring evolution of pathogen populations. Firstly, it is almost 
impossible to eliminate the source of infection from the farm. In ponds and marine cage 
systems reinfection from sediments, wild fish and other aquatic inhabitants is unavoidable 
(1, 7, 8). Even in completely enclosed recirculating systems, economics dictate that the 
system cannot be shut down and disinfected completely, thus populations of the pathogen 
are likely to remain in biofilms on the pipe work, tanks and filters. Secondly, the infectious 
agent, S. iniae is highly variable (6, 12, 26), with its major antigenic determinant, 
polysaccharide capsule (6, 18, 21), being highly polymorphic: Novel capsular serotypes 
have already led to vaccine failure in fish farms in several parts of the world, including 
Australia (1, 4, 11, 26). Finally, in Australia, there is no licensed generic vaccine against S. 
iniae so autogenous vaccines (‘custom’ vaccines prepared from an isolate taken directly 
from the original farm and only used on that farm) are routinely employed to prevent 
streptococcosis. This creates a closed cycle whereby a pathogenic strain isolated from a 
particular farm is used to prepare a vaccine that is then used to vaccinate stocks that are 
reintroduced onto the same farm. 
The capsular polysaccharide (CPS) is located on the outermost layer of bacterial cells and 
are ubiquitous across several bacterial species (28). For pathogenic Streptococcus 
species, CPS varies depending on serotype and is a recognized virulence factor that 
contributes to immune evasion (10, 18). In Group B Streptococcus (Streptococcus 
agalactiae), variations in the polysaccharide capsule have been implicated in reduced 
complement C3b binding, and ultimately avoidance of phagocytosis (19). Similarly, 
research on Streptococcus pneumoniae revealed that morphological changes in the 
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capsule occur in order to adapt to the host’s environment (13). In Streptococcus iniae, as 
with the other streptococcal species, production of the capsular polysaccharide appears to 
be necessary for infection (21). Locke and colleagues (2007) elegantly demonstrated that 
cpsD, a homologue of a gene shown to be required for CPS production in Group B 
Streptococcus and S. pneumoniae, was required for capsule formation and export in S. 
iniae. Although a few studies have investigated virulence factors in S. iniae, the function of 
the genes in the capsular operon are less well known, and how these translate into 
multiple serotypes in this species is yet to be elucidated. 
In the present study, we investigated molecular evolution of the capsular operon of S. iniae 
from diverse origins in order to determine which genes were most variable. We found that 
five genes out of the approximately 21-kb cps operon were highly variable, and when we 
investigated case studies of repeated autogenous vaccination and vaccine failure at 
Australian barramundi farms for links between the highly mutable genes and reinfection of 
vaccinated stock, we found a direct correlation with the variable cps genes and vaccination 
failure. Surprisingly, no capsule was formed in some of our isolates, yet the pathogen was 
still able to infect the host, albeit with a completely different pathology. To further 
understand these findings on the effect on vaccination against S. iniae, we examined 
serological cross-reactivity using antibodies raised in fish between isolates with differing 
cps gene sequences from several of the case studies in which vaccinated stock became 
reinfected. Our results suggest that polyvalent vaccines comprising different cps sequence 
types are partially effective but that future generic vaccines may need to target alternative 
antigens that are less polymorphic than CPS.  
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2.2 Materials and Methods 
Bacterial strains and culturing 
Bacterial isolates received from culture collections or direct from fish farms or veterinarians 
were stored at -80 °C in Todd-Hewitt broth (THB) containing 20% glycerol until required, 
and are listed in Supplementary Table 1. Strains were recovered from stock without 
defrosting and grown on Columbia Agar base containing 5% defibrinated sheep blood 
(Oxoid, Australia) at 28 °C for 24-48 h. Where isolates were obtained from farm cases 
through veterinarians, histopathology was performed by the veterinary laboratories using 
standard techniques. Identity of strains was confirmed by diagnostic PCR as previously 
described (20, 27), and by sequencing the 16S rRNA gene (26, 27).
DNA extraction, primer design, PCR, and sequencing  
S. iniae genomic DNA was extracted from freshly-grown cells using an enzymatic lysis 
method as previously described (27a). Primers for PCR and sequencing were designed 
using the S. iniae capsule operon sequence available on GenBank (sequence accession 
number AY904444). The primers used were as described in Barnes (5) and are listed in  
Tables S2 and S3 in the supplemental material.  
Capsular operon genes were amplified individually or in blocks of several genes (see 
Table S2 in the supplemental material) with a proofreading DNA polymerase (PrimeStar 
HS DNA polymerase, Takara, Japan) in 25 µL reactions composed of: 5 µL of 5 x PCR 
buffer, 0.5 µL of 4 x 2.5 mM dNTP’s, 100 ng of each primer, 0.15 µL of PrimeStar DNA HS 
DNA polymerase, 100-200 ng of extracted bacterial DNA, and the balance made up of 
sterile Milli-Q water. Reactions were carried out at annealing temperatures appropriate to 
each primer pair (see Table S2 in the supplemental material) (5). A “hot start” technique 
was employed to reduce the likelihood of non-specific amplification products prior to 
cycling as follows: 2 min at 94 °C for one cycle, followed by 35 cycles of denaturation for 
15 s at 94 °C, 30 s at an appropriate annealing temperature, and extension at 72 °C of 1 
min for every expected kb of amplicon. Reaction mixtures were analysed by agarose gel 
electrophoresis. 
Where a single amplicon was produced, 0.6 µL of PCR product was added to 0.3 µL of a 
1:2 mixture of Exonuclease I and Shrimp Alkaline Phosphatase and 3.1 µL of sterile Milli-Q 
water and incubated at 37 °C for 30 min followed by heating at 85 °C for 15 min before 
being sent for DNA sequencing by the Australian Genome Research facility (AGRF, 
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Brisbane, Australia). Where more than one amplicon was observed (rarely), they were 
excised from the gel with a sterile scalpel blade and then extracted from the gel slice using 
a commercial gel purification kit for subsequent sequencing (MEGA-Spin Gel Extraction Kit, 
Intron Biotechnology, Korea).  
Chromatograms were analysed using Sequencher V 4.9 (Genecodes). Contigs were 
assembled using equivalent genes from the published genome as references and the 
assembled complete cDNA sequences were compared to the reference sequences using 
both nucleotide and translated variance tables in Sequencher 4.9. Sequence Types (STs) 
were assigned on an ad-hoc basis as discovered, with the sequence types for the type 
strain assigned ST1. Changes resulting in an amino acid change were assigned ST 
numbers while synonymous nucleotide changes were denoted with a letter appended to 
the identical amino acid sequence type. Sequences for each of the STs of cps genes were 
uploaded to GenBank as follows: cpsY ST1 and ST2, GenBank accession numbers 
JX164243 and JX164242, respectively; cpsD ST1, ST2, ST3, ST3A, and ST4, GenBank 
accession numbers JX164238, JX164245, JX164246, JX164239 and JX164247, 
respectively; cpsE ST1, ST2, ST3, ST4, ST5A, ST5, ST6, ST7, and ST8, GenBank 
accession numbers JX164231, JX164248, JX164232, JX164233, JX164249, JX164234, 
JX164235, JX164236, JX164237, and JX164250, respectively; cpsG ST1, ST2, and ST3, 
GenBank accession numbers JX164240, JX14244, and JX164241, respectively; and cpsH 
ST1, GenBank accession number JX181784. 
Buoyant density assays 
As an estimate of quantity of CPS expressed by differing strains, buoyant density was 
determined in continuous Percoll gradients as described previously (17). Briefly, a 
standard isotonic Percoll solution was prepared by mixing 9 parts Percoll with 1 part 1.5 M 
NaCl. Mid exponential phase and stationary phase THB cultures of each strain were 
washed in PBS and resuspended to an optical density (600 nm) of ~2.5 and a 0.5 mL 
aliquot was layered onto the Percoll. All gradients were centrifuged simultaneously in an 
Eppendorf 5518E refrigerated centrifuge at 4000 x g for 90 min with no brake. The 
experiment was repeated using new cultures at least twice. 
Serological cross-reactivity by a whole-cell enzyme-linked immunosorbent assay 
(ELISA)  
Lates calcarifer (barramundi) weighing 35 g were obtained from a commercial farm and 
held in 300 L round plastic tanks with aerated brackish (5 ppt) water at 30 ± 1 °C 
connected to a recirculating system. Water quality was maintained with mechanical and 
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biological filtration, checked daily and water changes were conducted when required. The 
fish were acclimated for 7 days and were fed to satiation with commercial pelleted diet 
(Ridley Aqua Feeds, Narangba, Australia). 
Fish were anaesthetised with Aqui-S (Aqui-S, Lower Hutt, New Zealand) in accordance 
with the manufacturer’s instructions then vaccinated by intraperitoneal (i.p.) injection with 
100 µL of oil-adjuvanted (1:1 emulsion in Freund’s incomplete adjuvant) formalin killed 
bacterin. Control fish were injected IP with PBS/adjuvant emulsion. Fish were allowed to 
recover in clean aquarium water before returning them to their respective tanks.  
A total of 900 degree days postvaccination (i.e., 30 days at 30 °C), the fish were 
euthanized by lethal overdose of anaesthetic (Aqui-S) and bled by caudal venipuncture. 
Blood samples were allowed to clot at 4°C overnight and were centrifuged at 6000 x g for 
15 min to collect serum that was then stored at -20 °C for subsequent analysis.  The 
specific antibody response of each individual vaccinated fish was determined using 
enzyme-linked immunosorbent assay (ELISA) as described previously (9) with 
modifications. Microlon flat-bottom 96-well ELISA plates (Greiner) were coated by 
evaporating 100 µL/well of formalin inactivated suspension (OD600 = 1.0) of QMA0177, 
QMA0191 in coating buffer (carbonate-bicarbonate buffer [Sigma, Australia]) with a hair 
dryer. Coated plates were washed 3 times with tris buffered saline containing 0.1% Tween 
20 (TBST) and blocked with 2% normal goat serum in TBST at room temperature for 1 h. 
The plates were washed 3 times with TBST and 100 µL primary antisera from vaccinated 
fish and control serum from sham vaccinated siblings was diluted 1:4 in TBST and 
incubated for 2 h at room temperature. Wells were washed 3 times with TBST and 
secondary antibody (monoclonal mouse anti-barramundi IgM, diluted 1: 32-fold in TBST 
[Aquatic Diagnostics, Stirling, United Kingdom]) was added and incubated for 1 h at room 
temperature. Wells were washed three times with TBST before addition of tertiary antibody 
conjugate (polyclonal goat anti-mouse IgG alkaline phosphatase conjugate, diluted 1: 
30,000 in TBST [Sigma Aldrich]) and incubated for 1 h at room temperature. Wells were 
washed twice in 0.1% TBST and once in TBS, then colour was developed for 1 h using p-
Nitrophenyl phosphate liquid substrate (50 µL/well) (Sigma Aldrich). Absorbance was 
measured at 405 nm with a Fluostar Optima spectrophotometer/fluorimeter/luminometer 
(BMG LabTech).  
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2.3 Results 
Variation in capsular genotype is confined to a few genes in the operon 
Capsular biosynthesis in S. iniae is under the control of a 21-kb operon containing around 
20 genes. The operon has been fully sequenced (21) and characterized to some degree 
using site directed mutagenesis (18). To determine whether genetic changes in the 
capsular operon correlate with infection in vaccinated animals and virulence, we initially 
sequenced all genes within the capsular operon of 10 S. iniae isolates. These strains 
came from diverse origins and included strains from documented vaccine failures (4, 5, 26).  
Sequences of the genes from the capsular operon of these 10 isolates resulted in a 
number of surprising findings (Table 1). First, the number of synonymous (noncoding) 
mutations across the 21-kb operon was incredibly low, compared to coding mutations, 
which occurred frequently. Coding mutations, resulting in amino acid changes in the 
expressed proteins, were restricted to a limited set of genes within the operon. That is, the 
mutations were not evenly distributed across all of the 21 kb but were confined to a limited 
set of 5 genes, cpsY, cpsD, cpsE, cpsG, and cpsH (Table 1).   
Table 1 Sequence types of genes from the capsular operon of 10 isolates of S. iniae 
separated either geographically or serologicallya 
Gene 
ST for each strain no. (origin) 
QMA0
072 
QMA
0076 
QMA
0083 
QMA
0140 
QMA
0155 
QMA
0165 
QMA
0177 
QMA
0191 
QMA
0188 
QMA018
6 
QLD QLD WA USA NSW QLD NT NT ISR ISR 
cpsY       2 2   
cpsD 3 3 3  3 3 3 3 3A 2 
cpsE 3A 4 3  3 3A 3 3 2 2 
cpsG   2  2  3  X X 
cpsH      2     
a Gene sequences from the type strain (QMA0140) were designated ST1. As coding mutations were 
discovered, they were allocated a new sequence type number arbitrarily in the order of discovery. Non-
coding mutations are given the ST number of the identical expressed sequence and identified as variants 
with a letter (eg. ST3A expresses the same protein as ST3 but has one or more non-coding single nucleotide 
polymorphisms [SNPs]). Genes are ST1 if not otherwise indicated. X indicates a deleted gene. Only genes 
that differ from the type strain are included in the table. Strain geographic origin abbreviations: QLD, 
Queensland, Australia; WA, Western Australia; NSW, New South Wales, Australia; NT, Northern Territory, 
Australia; USA, United States of America; ISR, Israel. 
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Subsequently, we extended our study to an additional 29 isolates and sequenced blocks 
of genes encompassing these regions (Table 2). We found that cpsE had the largest 
diversity (that is, the largest number of variant sequence types [STs]). However, cpsE was 
not the most frequently modified gene in the operon; variance in cpsG occurred more 
frequently in Australian isolates (see Table S1 in the supplemental material) (5). cpsD was 
also variable, with 4 different coding sequence types found among the isolates sequenced. 
In contrast, diversity of cpsD was lower in Australia, with only two sequence types found.  
Table 2 Nucleotide and amino acid changes associated with differing cps gene sequence types 
Gene and 
position 
Nucleotides/amino acids ina: 
ST1 ST2 ST3 ST4 ST5b ST6b ST7 ST8 
cpsY         
 535/179 TTC/F TCC/S       
cpsD         
    367/123 CCA/P  CTA/L      
    385/129 TTA/L        
    475/175 GTG/V TTG/L TTG/L      
cpsE         
    119/40 GAA/E GGA/G GGA/G GGA/G  GGA/G GGA/G GGA/G 
    136/46 TTT/F  GTT/V      
    1426/476 CGT/R   CTT/L     
    1081/361 CAT/H    Del C→ Del C→   
    1108/370 TTA/L    TAA/stop TAA/stop   
    1096/366 AAG/K      ACG/T  
    1315/439 GCA/A       GTA/V 
cpsG         
    495/165 TTA/L Del TTA/L       
    498/166 TCA/S Del TCA/S       
    501/167 AAG/K Del AAG/K       
    504/167.1   Ins TTA/L      
    507/167.2   Ins TCA/S      
    510/167.3   Ins AAG/K      
cpsH         
    669/223 TTA/L TTT/F       
a Underlining indicates the changed nucleotide relative to the type strain (ST1). Del, deletion; ins, insertion. 
b A single nucleotide deletion leads to a changed amino acid sequence from aa 361 to an early termination 
at aa 370. 
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Indeed, ST3 was universal across all states in Australia, and ST1 was identical to the type 
strain from dolphins, arising only under high selective pressure in two cases in New South 
Wales and South Australia (see Table S1 in the supplementary material; see also the case 
histories described below). The cpsY gene also had low variability; all isolates examined 
carried ST1, regardless of global geographic origin with the exception of the isolates from 
Northern Territory, Australia, that, without exception, carried the ST2 cpsY variant (Table 
2).   
Coding mutations in the capsular operon correlate with autogenous vaccine failure 
Reoccurrence of infection by S. iniae in vaccinated fish has been reported previously in 
Israel (4), and this appeared to be a result of changes in capsular polysaccharide and 
secreted exopolysaccharide (11). We sequenced the complete capsular operon in two 
postvaccine strains from Israel that had differing random amplified polymorphic DNA 
(RAPD) profiles (4) but that were apparently serologically cross-reactive (4, 11) and found 
a single coding mutation in cpsD (Table 1) resulting in a change from proline to leucine at 
amino acid (aa) position 123.  
Northern Territory, Australia                                  
In April 2005, streptococcosis emerged as a cause of high mortalities in farmed 
barramundi in Port Hurd, Northern Territory (NT), Australia. In July 2005, a cohort of 
fingerlings was vaccinated with an autogenous vaccine prepared from the isolate obtained 
from the index case and designated strain QMA0191 in the UQ strain collection (Table 3) 
and introduced onto the site. Further cases of clinical streptococcosis were recorded in the 
fish at Port Hurd in July, August and September, as well as isolated from brain and kidney 
in subclinically infected fish. All these cases were in nonvaccinated fish and are 
represented by strain numbers QMA0142, QMA0150, and QMA0153 (Table 3). In July 
2006, an outbreak of clinical streptococcosis occurred in multiple cohorts of fish across the 
farm, including fish vaccinated with the autogenous vaccine containing strain QMA0191. 
An isolate taken at this time was also deposited in the UQ collection and designated 
QMA0177.  Analysis of the capsular genotypes of the strains recovered from unvaccinated 
fish during 2005 indicated a consistent molecular serotype identical to the strain 
(QMA0191) used to produce the autogenous vaccine and explains the efficacy of the 
vaccine (Table 3). When disease arose across the site in July 2006, more than 6 months 
after vaccination, mortality resulted from strains with a coding change in cpsG, a 6-amino-
acid (2 x LSK repeat) insert.  
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TABLE 3 Case histories of strain isolation and vaccination in three farms, a sea farm in Northern 
Territory and recirculating aquaculture farms in South Australia and New South Walesa 
  ST of:     
Location Strain cpsD cpsE cpsG Isolation date 
(mo/yr) 
Dates used 
in vaccines 
Northern Territory 
 
QMA0191 (v) 3 3 1 04/2005 2005-2006 
 QMA0142 3 3 1 07/2005  
 QMA0150 3 3 1 08/2005  
 QMA0153 3 3 1 09/2005  
 QMA0177 3 3 3 07/2006  
South Australia QMA0160 (v) 3 3 1 12/1999 2004-2009 
 QMA0159 3 3 2 03/2006  
 QMA0243 3 3 2 05/2006  
 QMA0244, QMA0245 3 3 2 10/2008  
 QMA0246+,QMA0247,QMA0248 3 3 2 03/2009 March/April 
2009 
divalent 
 QMA0249 1 5* X 05/2009  
New South Wales  QMA0155 (v) 3 3 2 12/2005 Early 
2006 
Monovalent 
 QMA0220+ 3 3 2 08/2006 2007-2008 
 QMA0250+ 3 3 2 11/2007 January 
2008 
 QMA0251+, QMA0252+ 3 3 2 06/2008 July 
2008 
divalent 
 QMA0233 1 5A* X 11/2008  
 QMA0253+, QMA0254+ 1 5A* X 01/2009 March   
2009 
divalent 
 QMA0236 1 5A* X 03/2009  
a Numbers indicate sequence types of indicated cps genes. X indicates a gene deletion. All other genes in 
the cps operon were identical among strains in the same table unless otherwise indicated. *, strain had 
genes cpsF-cpsM deleted; (v), strain used in initial autogenous vaccine; +, isolate used in subsequent 
vaccinations. 
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South Australia  
Vaccination of barramundi in a tank-based aquaculture facility in South Australia (SA) 
commenced in late 2004 using an autogenous vaccine prepared from an isolate from an 
outbreak in December 1999 (QMA0160). A subsequent outbreak in May 2006 resulted 
from a new strain (QMA0243) and again in October 2008 (QMA0244, QMA0255) 
continuing through the southern hemisphere summer to March 2009 (QMA0246 to 
QMA0248), with all isolates exhibiting a shift in amino acid composition in the cpsG (ST1 
and ST2) genes (Table 3). A new autogenous vaccine incorporating both strain types was 
used to vaccinate new stock in March to April 2009. In May 2009, low-level mortality was 
detected in vaccinated stock, but symptoms were atypical; barramundi developed spinal 
fractures. In some vaccinated fish, these spinal fractures were colonized by Gram-positive 
cocci; perpetuating spinal inflammation (Fig. 1).  
FIG 1 Histopathology of spinal inflammation in infected barramundi. (A) L. calcarifer sagittal spinal 
vertebral section showing normal structure of central vertebral spongy bone trabeculae, indicated 
by T, and endplate, indicated by E, at X40 magnification (hematoxylin and eosin [H&E]). (B) L. 
calcarifer spinal sagittal section at the point of collapse, indicated by C, of the intervertebral disc 
space due to inflammatory infiltrate and fracture of the vertebra, indicated by F, at X40 
magnification (H&E). (C) L. calcarifer spinal sagittal section showing multiple colonies of Gram-
positive cocci. Arrows indicate inflamed and necrotic tissue exudate, indicated by N, at the site of 
spinal fracture at X200 magnification (H&E). (D) L. calcarifer spinal sagittal section showing a 
severe intraspinal canal infiltration with inflammatory cells, caseous necrotic foci, indicated by N, 
containing colonies of phagocytosed coccoid bacteria. Inflammatory exudate is in close proximity 
to the spinal cord, indicated by S, at X40 magnification (H&E). (E) Gram stain of an L. calcarifer 
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sagittal spinal section showing colonies of Gram-positive coccoid and chain-forming bacteria in 
close association with the vertebral bony surfaces at X1,000 magnification. (F) Gram stain of an L. 
calcarifer spinal vertebral inflammatory exudate showing multiple Gram-positive coccoid bacteria. 
Note the potentially phagocytosed bacteria in cells (arrows), but there are also free bacteria in the 
exudate, at X1,000 magnification. 
The brain and head-kidney (pronephros) of nine fish were sampled for bacteria, but no S. 
iniae was recovered, nor was S. iniae observed in the kidney during histology. S. iniae was 
only observed in, and recovered from, only the bone lesions and the resulting exudate (Fig. 
1). The isolates that caused this unusual pathology were found to have a frameshift 
mutation (single nucleotide deletion at nucleotide [nt] position 1081) in the cpsE gene that 
resulted in an early stop codon at amino acid 370, resulting in a severely truncated protein. 
Moreover, all of the capsular operon genes from cpsF-cpsM were deleted in these isolates 
(Table 3). 
New South Wales, Australia 
A similar but separate case occurred at a recirculating aquaculture farm in NSW: 
barramundi were vaccinated with autogenous bacterins prepared from isolates QMA0155 / 
QMA0220 that caused an outbreak that ran from late 2005 into early 2006. In November 
2008, an outbreak occurred in vaccinated stock. As with the SA case, mortalities were low 
and associated with spine deformities in which streptococci were able to be detected in 
histology and from which S. iniae was subsequently isolated in culture. These isolates had 
a similar frameshift mutation in cpsE, coupled with deletion of cpsF-cpsM (Table 3). 
Changes in genotype associated with vaccine failure are phenotypically and 
antigenically relevant  
In the vaccine failure case in Northern Territory, Australia, a single mutation was found in 
the cpsG gene (from ST1 to ST3). A buoyant density assay was performed to assess any 
phenotypic variation between the cps genes.  Buoyant density was different in the two 
isolates, with isolate QMA0177 traveling further through a continuous Percoll gradient than 
strain QMA0191. This occurred with multiple independently prepared cell suspensions 
through Percoll gradients prepared at two dilutions. In the case of the SA and NSW cases 
with truncated cpsE and major deletions in the operon, the differences in buoyant density 
were more pronounced, with the mutated isolates QMA0253, QMA0236, and QMA0249 
migrating completely through the continuous gradient when prepared using diluted Percoll 
(Fig. 2). 
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FIG 2 Percoll buoyant density assay for NT (QMA0177, QMA0191), SA (QMA0160, QMA0243, 
QMA0249), and NSW (QMA0155, QMA0220, QMA0236, QMA0253) isolates. 
To investigate whether the changes seen in capsular operon that coincided with 
reinfection of vaccinated fish were antigenically relevant, antibodies were raised in 
barramundi against the two isolates from the index case of reinfection in NT. Antibodies 
raised against QMA0191 were poorly cross-reactive with QMA0177 by a whole cell ELISA 
(Fig. 3A). Similarly, antiserum raised against QMA0177 was poorly cross-reactive with 
QMA0191. In the case of the strains from NSW, antisera raised in barramundi against the 
initial vaccine isolate QMA0155 (same CPS sequence type as the subsequent vaccine 
strains QMA250 to QMA252) cross-reacted strongly with strain QMA0236, which occurred 
in vaccinated fish (Fig. 3B). When fish were vaccinated with QMA0236, a relatively low 
antibody response was detected in general, even against the same strain in a whole-cell 
ELISA, although it was higher than that for the negative control serum. Although the 
response was low, it was significantly higher in a whole-cell ELISA against the 
homologous strain than against QMA0155 (Fig. 3B)(p < 0.05). 
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FIG 3 Antibody cross-reactivity by a whole-cell ELISA for selected isolates from the index case in 
NT (QMA0177, QMA0191) (A) and the NSW case (QMA0155, QMA0236) (B). 
2.4 Discussion 
Vaccination of finfish against bacterial pathogens has proven extremely effective at 
preventing mass mortality in farmed animals (29). However, it is this very efficacy that 
places a high selective pressure on pathogens and this may lead to dominance by new 
serotypes less well recognized by the resultant specific immune response to the original 
vaccine. In the present study, we investigated genetic changes in S. iniae, a fish pathogen 
with a track record of new serotype emergence in vaccinated animals (4). We found 
mutations in the capsular operon that coincided with infection in previously vaccinated 
stocks. These genetic changes likely lead to changes in polysaccharide biosynthesis (6, 
11). Intriguingly, changes were restricted to a limited suite of genes within the ~ 20-gene 
operon. Firstly, two sequence types were found in cpsY. Of 39 isolate sequences, only 
strains from the Northern Territory, Australia, contained the cpsY ST2 variant, with all other 
isolates being identical to the type strain. It is intriguing that a new sequence type should 
only be found in NT, especially when movements of fingerlings interstate are common. 
This suggests that S. iniae infections arose locally in the fish after they were shipped and 
the bacterium was not cotransported with the fingerlings from the Darwin hatchery. cpsY 
ST2 would currently appear to be a robust diagnostic indicator for NT origin of the strain. 
cpsY is a transcriptional regulator that has an important role in intracellular survival in 
neutrophils, and is also essential for successful dissemination to the brain (2, 3). The 
functional role of the mutation in the present case is unknown, but isolates were recovered 
from the brain in both outbreaks. 
cpsA through cpsC were always identical to the Type strain, regardless of country of origin. 
In S. pneumoniae cpsD is a self-phosphorylating tyrosine kinase, acting with cpsB and 
cpsC to regulate activity of cpsE (22-25). cpsD was found to vary in S. iniae, and was the 
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only coding mutation in the cps operon that was different between the two post-vaccine 
isolates from the Israeli case of vaccine failure, with a switch in the amino acid at position 
123 from proline to leucine. While the effect of this mutation at the functional level remains 
to be determined, a proline-leucine switch at this position will substantially change the 
shape of the protein, removing a bend at this residue. The Israeli team reported that these 
two isolates (named KPF177 [QMA0188] and KPF404 [QMA0186]) were serologically 
similar when tested with rabbit antisera using Ouchterlony immunodiffusion, but they differ 
in RAPD profiles (4). Each of these strains has been used in autogenous vaccines and a 
novel serotype arose which differed in EPS production (11). It would be interesting to 
investigate the CPS operon of the newly emerged strain to determine whether coding 
mutations have arisen in the capsular biosynthesis machinery that led to increase 
polysaccharide over-expression, or failure to anchor the membrane. In Australia, a coding 
mutation in cpsD was never found as the sole mutation in the cps operon with most 
isolates analysed having the ST3 cpsD sequence type. The only other cpsD variant found 
in Australia isolates was cpsD ST1 and this was only found in association with a frame 
shift mutation in cpsE. Once again this cpsD mutation (ST3 to ST1) involved the proline-
leucine switch at aa 123, derived from an identical single nt mutation. In Australia, 
however, the proline-leucine switch was also accompanied by a valine-leucine substitution 
at aa 175. The effects of cpsD mutations will be difficult to interpret in Australian isolates 
due to the universal accompaniment of the change with a frame shift in cpsE. In S. iniae, 
cpsE encodes a UDP-glucose-dependent glycosyl transferase that initiates synthesis and 
export of the capsular polymer. There was more diversity of this gene than any other of the 
cps genes, with 6 different sequence types found among the S. iniae isolates recovered in 
Australia, and 8 in total among the 39 isolates analysed. It is likely that mutations in this 
gene change the amount of capsular polysaccharide produced and this can have profound 
effects on the tissue distribution of the organism during disease (18). Indeed, the frame 
shift mutations that resulted in early termination of the cpsE gene that occurred in strains 
infecting vaccinated fish in NSW and SA substantially increased the buoyant density, 
suggesting reduced/eliminated capsular polysaccharide production. This was associated 
with lower mortality and completely transformed pathology and symptoms. While these 
mutations often co-occurred with deletion of genes cpsF through cpsM (isolates 
QMA0233-236; isolate QMA0249), it appears that the frame shift mutation in cpsE alone is 
sufficient to cause the phenotypic changes as isolate QMA0158 (frame shift in cpsE, but 
remainder of the operon intact) exhibited similar increase in buoyant density to the strains 
carrying the deletion of cpsF-M. Deletion of cpsF-M has been reported previously in a 
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“commensal” strain S. iniae (18). Our research suggests that these strains are not 
commensal, as they still cause pathology and mortality in a farm situation, but are 
somewhat attenuated (data not shown). This association with spinal fractures in 
barramundi is interesting as human spinal osteomyelitis caused by Streptococcus 
dysgalactiae subsp. equisimilis has been reported (14). The structure of teleost fish bone 
is without a marrow cavity and Haversian system, which means that osteomyelitis cannot 
occur. However, inflammation can develop in avascular tissue by extension from the 
adjacent periosteal vessels and generally takes the form of rarefaction (demineralization) 
rather than frank necrosis. Teleost bone usually cannot be immobilized in a fracture 
situation and thus will heal in a deformed fashion, as observed in the cases reported here 
(data not shown). 
cpsG is a putative UDP-glucose 4 epimerase that converts UDP-glucose to UDP-
galactose. Three variants of cpsG, involving an insertion or deletion of three amino acids, 
LSK, at aa positions 165, 166, and 167 in the ST1 type strain, were found. In ST2, these 
three amino acids were deleted, while in ST3, they were repeated, resulting in a protein 
that was three amino acids longer than the type strain. The phenotypic effects of these 
mutations remain to be determined, but mutations in this gene that alter enzyme efficiency 
may change the rate of conversion and thus change the ratio of glucose/galactose in the 
final capsular polymer, with resulting effects on surface epitopes. Mutation from cpsG ST1 
to ST3 was the only change in the index case of vaccine failure in Australia. This involves 
a 3-aa LSK repeat insertion in ST3 compared to ST1. How this may affect function is yet to 
be elucidated, but the two isolates involved were serologically different, as determined by 
an ELISA using fish antiserum. Moreover, there was a small change in the buoyant density 
of the cells, suggesting a change in CPS structure. Future work will focus on expressing 
these variants as recombinant proteins and measuring their epimerase activity. This, 
coupled with LC-MS analysis of CPS from these two isolates, may elucidate how these 
mutations translate into antigenic variation. cpsG was deleted in a number of isolates, 
including the Israeli and Thai isolates, suggesting that it may not be essential for cps 
biosynthesis but may play an important role in the final molecular shape of the 
polysaccharides. 
No cases of reinfected vaccinated fish have yet been associated with changes in cpsH, 
although two variants were found among the Australian strains. cpsH is a putative repeat 
unit polymerase, and changes in efficacy may change polymer length and, therefore, the 
final structure and antigenic nature of the capsule. 
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When disease arises in enclosed tank-based aquaculture systems, theoretically, best 
practice would be to close down the system, disinfect it completely, dismantle and clean 
pipework, pumps and filtration, then restart with clean stock. In practice this is not possible 
as multiple size-classes are generally kept within the same system to allow continual 
supply of table-sized fish for customers. Thus, outbreaks of S. iniae may be controlled with 
careful antibiotic treatment, and vaccinated stock may be reintroduced into the system. 
However, this means that the reservoir of infection is never really eradicated, providing 
ample opportunity for reinfection should immunity become compromised. In the closed 
systems in NSW and SA, careful use of autogenous vaccines initially controlled disease. 
In the latter period of the study, divalent vaccines were formulated after sequence typing to 
include the cps STs from the history of infection on the farm. It is intriguing that 
streptococcosis once again occurred in these farms in 2008/2009 but with substantially 
changed pathology and greatly reduced mortality among the infected fish. Moreover, 
strains from both sites were typed and found to carry the frameshift mutation in cpsE (cpsE 
ST5 / 5A) and the deletion of cpsF through cpsM, although fingerlings came from different 
sources. The development of these very similar cases suggests the possibility of a 
common origin for the isolate. However, a silent mutation after the early termination signal 
in cpsE was found in the NSW isolates (hence cpsE ST5A), hinting that the SA case and 
NSW case may have arisen independently. Interestingly, the unusual truncation of cpsE 
was also found in a strain isolated several years earlier in Thailand. Whether this type has 
been introduced or whether it is a natural adaptation to host specific-immunity that occurs 
independently is unknown. It is likely that such a serious mutation in the capsular operon 
results in complete cessation of the capsular biosynthesis machinery and therefore 
creates a capsule-deficient mutant, as evidenced by our buoyant density results. This may 
explain the unusual pathology and very low mortality rate in the fish, as a capsule deficient 
strain, while not recognised by anti-CPS antibodies, would be highly susceptible to 
phagocytic attack and may seek refuge in the bone of already-compromised fish. When 
antibodies raised against QMA0155, the initial sequence type found on this farm, were 
used in a whole cell ELISA, they cross-reacted with strain QMA0236 but not vice versa. 
This may reflect lack of cps in QMA0236; while whole-cell bacterins prepared with 
QMA0155 would result in anti-cps antibodies along with a range of antibodies against 
other cell components, including integral membrane proteins, which are highly conserved 
among S. iniae (6) and would be exposed to antibody binding on CPS-deficient QMA0236, 
the converse would not be true. Integral membrane proteins of QMA0155 would likely be 
coated with CPS and unavailable for antibody binding in a whole-cell ELISA. 
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In summary, coding mutations in the capsular operon of S. iniae appear to correlate with 
reinfection of previously vaccinated fish. These mutations are restricted to a few key genes 
in the ~20-gene operon. Two key questions remain to be answered. First, how do the 
genetic changes in the capsular operon, translated changes in the protein machinery for 
polysaccharide biosynthesis and export, actually lead to phenotypic and antigenic changes 
on the surface of the cell? Second, is vaccination driving mutation of highly mutable loci 
within a single strain type extant on a farm at a particular time, or is vaccination merely 
selecting the fittest variant from a pool of varied serotypes that are present among the 
population? The high ratio of nonsynonymous to synonymous mutations (dN/dS) among 
the genes of the CPS operon suggests that these changes are being driven under strong 
selective pressure. Further work aimed at answering these questions is ongoing. 
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Abstract 
Background: Streptococcus iniae causes septicaemia and meningitis in marine and 
freshwater fish wherever they are farmed in warm-temperate and tropical regions. 
Although serotype specific, vaccination with bacterins (killed bacterial cultures) is largely 
successful and vaccine failure occurs only occasionally through emergence of new 
capsular serotypes. Previously we showed that mutations in vaccine escapes are 
restricted to a limited repertoire of genes within the 20-gene capsular polysaccharide (cps) 
operon. cpsG, a putative UDP-galactose 4-epimerase, has three sequence types based 
on the insertion or deletion of the three amino acids leucine, serine and lysine in the 
substrate binding site of the protein.  
Results: To elucidate the role of cpsG in capsular polysaccharide (CPS) biosynthesis and 
capsular composition, we first prepared isogenic knockout and complemented mutants of 
cpsG by allelic exchange mutagenesis. Deletion of cpsG resulted in changes to colony 
morphology and cell buoyant density, and also significantly decreased galactose content 
relative to glucose in the capsular polysaccharide as determined by GC-MS, consistent 
with epimerase activity of CpsG. There was also a metabolic penalty of cpsG knockout 
revealed by slower growth in complex media, and reduced proliferation in whole fish blood. 
Moreover, while antibodies raised in fish against the wild type cross-reacted in whole cell 
and cps ELISA, they did not cross-opsonise the mutant in a peripheral blood neutrophil 
opsonisation assay, consistent with reported vaccine escape.  
Conclusions: We have shown here that mutation in cpsG results in altered CPS 
composition and this in turn results in poor cross-opsonisation that explains some of the 
historic vaccination failure on fish farms in Australia. 
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3.1 Introduction 
Aquaculture currently supplies more than half of the finfish consumed annually and is now 
recognised as a major contributor to future food security against a background of 
continuing human population growth (1). However, the rapid growth of finfish aquaculture 
has encountered a number of challenges to environmental and economic sustainability 
including high losses from infectious diseases (2, 3). Vaccination of fish in aquaculture has 
transformed the control of mass mortality from bacterial diseases since the introduction of 
water-in-oil emulsion injectable vaccines in the 1990s, resulting in reduction in antibiotic 
use to negligible levels in industries where vaccination is routinely applied (4, 5). Widely 
employed for more than 20 years in the cold and cool-temperate water salmonid 
aquaculture industries, vaccination by injection is being adopted in warm-temperate and 
tropical aquaculture species where industry expansion is currently most rapid and novel 
disease challenges arise (6). In most cases, water-in-oil emulsion injectable fish vaccines 
provide lifetime protection through the farm cycle and protective efficacy has remained 
stable through many years of repeated use to vaccinate each new year-class of animals 
stocked into farm sites (5).  Occasionally, however, reinfection of vaccinated fish does 
occur. For example, in salmonids, a novel biotype of Yersinia ruckeri emerged 
independently in rainbow trout in Europe and the USA that was not fully covered by 
existing Y. ruckeri vaccines (7-11). In warm water aquaculture, protection against S. iniae 
is also type-specific with novel capsular serotypes emerging relatively rapidly in vaccinated 
stock (12-14). The occurrence of vaccine-escape among streptococcal fish pathogens 
after the introduction of vaccination into these rapidly developing warm-water industries is 
potentially problematic, but not without precedent: Serotype switching in Streptococcus 
species is frequently associated with reinfection and vaccine escape in humans and 
terrestrial animals (15-18). In human infants, both serotype replacement and serotype 
switching have occurred at low prevalence since the introduction of polyvalent 
pneumococcal vaccines in the early 2000s (16, 19, 20). The molecular mechanisms 
behind serotype change are not completely understood, however non-synonymous point 
mutation in wciP has been attributed to capsular polysaccharide (cps) serotype switching 
in serotype 6A pneumococcus in vaccinated infants in Japan (21), and mutational analysis 
has attributed nucleotide changes to differences in polysaccharide composition (22, 23). In 
S. iniae, mutations in several genes within the ~20 gene cps operon have been associated 
with vaccine escape (14). In-frame deletion or insertion of nine nucleotides in the cpsG 
locus has been most frequently associated with vaccine escape during the autogenous 
vaccination cycle (14).  
	 42	
The capsular operon of S. iniae has been sequenced and annotated previously and cpsG 
was identified in silico as a UDP-galactose-4-epimerase (24). Epimerases play an 
important role in bacterial exopolysaccharide biosynthesis in both Gram-negative (25-27) 
and Gram-positive bacteria (28, 29) in which they catalyse the interconversion of hexose 
sugar isomers, such as glucose and galactose, often as a conjugate with a nucleotide 
diphosphate and/or a lipid carrier (30). UDP-galactose 4-epimerase from E. coli 
interconverts UDP-glucose and UDP-galactose via a hydrogen transfer pathway in which a 
complex between the enzyme and a diphosphopyridine nucleotide (which is reduced in the 
process) forms the UDP-4-keto sugar as an intermediate (31, 32). This cyclical pathway 
can proceed in either direction, dependent upon substrate availability and removal of the 
end product into other pathways. As a result of this bidirectional capability, predictions of 
how the epimerase may influence the final polysaccharide capsule structure are difficult, 
however epimerase activity is directly correlated with the amount of exopolysaccharide 
produced by S. thermophilus (33, 34). Therefore one might postulate that a reaction 
favoured in one direction over the other may result in dominance of either glucose or 
galactose in the final polysaccharide structure.  
Given non-synonymous mutations in S. iniae cpsG are correlated with reinfections 
occurring in vaccinated fish, we examined the role of cpsG in S. iniae capsular 
polysaccharide (CPS) biosynthesis to determine how mutation of this gene may contribute 
to serotype switching and consequent vaccine escape. 
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3.2 Materials and Methods 
Bacterial strains and culturing 
Streptococcus iniae isolates collected from fish farms by veterinarians between 1995 and 
2014 were stored as master seed stocks at -80°C in Todd-Hewitt broth (Oxoid) containing 
20% glycerol until required and are listed in Table 1. Case histories are as described 
previously (14). Strains were recovered from stock without defrosting and grown on 
Columbia Agar base containing 5% defibrinated sheep blood (Oxoid) at 28°C for 24-48 h.  
S. iniae genomic DNA was isolated as described previously (35), and S. iniae identity and 
purity was confirmed by diagnostic PCR (36, 37), and by sequencing the 16S rRNA gene 
(36, 38).  All strains were grown in Todd-Hewitt Broth (THB) overnight at 28°C, with gentle 
shaking, unless otherwise stated. 
Table 1. Bacterial strains used in this study 
Strain cpsG ST Comment Reference 
QMA0142 1 Isolated from non-vaccinated fish 14 
QMA0177 3 Isolated from vaccinated fish 14 
QMA0248 2 Isolated from vaccinated fish 14, 43 
QMA0395 KO cpsG knockout from QMA0142 This study 
QMA0502 1 Rescue ST1 knock-in QMA0395 This study 
 
In silico analysis of cpsG 
Amino acid sequences for ST1, ST2 and ST3 variants of cpsG were analysed by BLAST 
using the conserved domain database (CDD) on NCBI 
(http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) to identify putative active sites, 
cofactor binding sites and the substrate-binding site. Amino acid sequences were also 
compared using Provean to predict potential effects of the insertion/deletion mutations on 
CpsG enzyme activity (39).  Molecular weights and pI were determined with ProtParam 
(http://web.expasy.org/cgi-bin/protparam/protparam). 
In-frame allelic exchange mutagenesis 
Wild type S. iniae isolate QMA0142 containing the ST1 variant of cpsG was used for allelic 
exchange mutagenesis.  Primers used for PCR were based on the cpsG gene from the S. 
iniae capsular operon found in GenBank accession number AAY17299.1. For allelic 
exchange, primers were designed to contain a region ~ 500 bp upstream and downstream 
of the S. iniae cpsG gene sequence, and adjacent primers to cpsG were designed 
containing ~ 25-bp 5’ extensions that parallel the 5’ and 3’ sequence of the spectinomycin 
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resistance (aad9) gene KC747117.1 (Fig. 1, Table 2). Phusion PCR reagents (New 
England Biolabs) were used to amplify upstream, downstream and complete 
spectinomycin amplicons, and to generate one fusion fragment, which was then cloned 
into pCR-Blunt-II (Invitrogen) to generate pCR-Blunt-ΔcpsG. The pCR-blunt-ΔcpsG 
construct was linearized by incubation with smaI and 10 µg of linearized DNA used to 
transform S. iniae isolate QMA0142 following a modified protocol (40), with incubations at 
30°C and spectinomycin (100 µg/ml) used for selection of allelic replacement mutants. For 
complementation of cpsG, a fusion construct was designed using cpsG ST1 amplified from 
strain QMAO142 with the addition of a constitutive promoter, ribosome binding site (RBS), 
and the antibiotic resistance gene chloramphenicol acetyltransferase (cat) from pACYC 
(41) downstream of the cpsG gene (Fig. 1).  Cloning and transformation was performed as 
above, except that chloramphenicol (4 µg/ml) was used for selection. Precise allelic 
exchange was confirmed by sequencing (Australian Equine Genetic Research Centre, 
Brisbane), and by PCR and RT-PCR as follows: Genomic DNA and RNA were purified 
from 5 mL mid-exponential THY cultures of WT QMA0142, mutant QMA0395 and rescue 
QMA0502 using DNeasy and RNEasy mini kits (Qiagen) according to the manufacturers 
protocol except that S. iniae cells were lysed with acid-washed glass beads (115 µm) for 
50s at 7000 rpm in a Roche MagnaLyser. For cDNA synthesis, genomic DNA was 
digested from the RNA extractions on-column with the RNAse-free DNAse set (Qiagen) 
and the eluted total RNA was quantified by Qubit spectrophotometry before 300 ng RNA 
per strain was reverse transcribed using SuperScript ViLo (Invitrogen). RT-PCR was 
performed with 2uL cDNA as template using cpsG, cpsF and cpsH primer pairs (Table 2, 
Figure 1).  Negative controls comprised non-transcribed RNA template with cpsF primer 
pair. Positive control was WT QMA0142 genomic DNA with each of the cpsF, G and H 
primer pairs. 
	45	
 
Figure 1. Schematic representation of in-frame allelic exchange mutagenesis for deletion and rescue of 
cpsG in S. iniae QMA0142. Knockout and rescue was confirmed by RT-PCR: A) cDNA template from 300ng 
total RNA extracted from QM0142 (WT), QMA0395 (mutant), QMA0502 (rescue), amplified with cpsF (lanes 
2-4), cpsG (Lanes 5-7) and cpsH (lanes 8-10) primers. B) Control amplification using non-reverse 
transcribed RNA as template with cpsF primers (negative control, lanes 2-4) and genomic DNA from 
QMA0142 (WT) with cpsF, cpsG and cpsH primers (positive controls, lanes 5-7). NEB 1kb markers are 
included in lane 1 in both gels. 
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Table 2. Primers used for in-frame allelic exchange and protein expression 
Primer Sequence (S, sense; A, antisense) Purpose 
Primers for allelic replacement of cpsG 
aad9 S 5’cgtggaatcatcctcccaaa3’ (S) spectinomycin gene 
amplification 
aad9 A 5’cactgcatttcccgcaatatc3’ (A) spectinomycin gene 
amplification 
cpsGFlankup 5’gcatggatccgacccgtctgccatgataac 3’(S) upstream sequence of cpsG 
cpsGFlankdown 5’ctgcgaattccggtctaaagttaaatcctcgc 3’ (A) downstream sequence of 
cpsG 
cpsGfusionUp 5’cgtatgtattcaaatatatcctcctcttttctcacttctccttattttgctctggtcc 
3’(A) 
upstream sequence of cpsG 
+aad9  
cpsGfusionDown 5’taactataaactatttaaataacagatttagaagtgtgttacaagggaaaa
aaattc 3’(S) 
aad9 + downstream sequence 
of cpsG 
cpsGintDown 5’cgatgctcctgctgaaatgccaactc 3’ (S) downstream internal cpsG 
cpsGintUp 5’gagttggcatttcagcaggagcatcg 3’ (A) upstream internal cpsG 
Primers for complementing cpsG 
compG1 5’caatagtcattttatgatttacaaatttagaagc 3’(S)  upstream primer of gene 
before cpsG, cpsF 
compG2 5’ctatattttttcattgtttctttccgatattcg 3’(A) end of cpsG 
compG3 5’cggaaagaaacaatgaaaaaatatagcgattcaaaataggagacattt
taaag 3’(S) 
RBS + cpsG 
compG4 5’ctttaaaatgtctcctattttgaatcgctatattttttcattgtttctttccg3’ (A) RBS + cpsG 
compG5 5’catttcaattgttcgcatcg 3’ (A)  cpsH downstream 
compG6 5’tggttaggagaaaaataaatgaaaaaatatagtagaagtgtgttac 3’ 
(S) 
cat + cpsH 
compG7 5’tatcggaaagaaacaatgaaaaaatatagcgattcaaaataggagac
attttaaag 3’ (S) 
cpsG + RBS 
compG8 5’gtaacacacttctactatattttttcatttatttttctcctaaccatgtctc 3’ (A) end of cat + cpsH 
catF 5’gaggattggaatagaaagccata 3’ (S) cat amplification  
catR 5’ttatttttctcctaaccatgtctca 3’ (A) cat amplification  
Primers for RT-PCR confirmation of expression in mutants 
cpsF F 5’atgtatccttatattaaacgac 3’(S)  
cpsF R 5’tcacttctccttattttgctctg 3’ (S) complete cpsF 
cpsG F 5’atgaaaaaagtacttattacaggtgc 3’ (S)  
cpsG R 5’ctatattttttcattgtttctttcc 3’ (S) complete cpsG 
cpsH F 5’atgaaaaaatatagtagaagtgtg 3’ (S)  
cpsH R 5’ttattcatcatcctgtttaatccctaaagta 3’ (A) complete cpsH 
 
Capsular polysaccharide (CPS) extraction and hydrolysis 
For CPS extraction, bacterial isolates were grown in 10 ml of THB overnight (Oxoid), and 
0.5 ml was inoculated into 45 ml of fresh THB and grown overnight at 28°C.  Cells were 
pelleted by centrifugation at 3,220 x g for 20 mins at 4°C (Eppendorf 5518E), and 
resuspended in 1 ml 150 mM Tris-HCl (pH 7.0), 1 mM MgSO4.  The suspension was 
	47	
transferred to a 1.5 ml microcentrifuge tube and centrifuged (Eppendorf MiniSpin) at 
12,100 x g for 10 min at room temperature.  After decanting, the pellet was resuspended 
with 1 ml 150 mM Tris-HCl (pH 7.0), 1 mM MgSO4 and 0.1% (w/v) of sodium 
deoxycholate, and incubated for 15 min at 37°C.  After incubation, 10 U/ml mutanolysin 
(Sigma), 100 µg DNaseI (Roche) and 100 mg RNaseA (Invitrogen) were added and the 
mixture was incubated for 18 h at 37°C. After incubation, 100 µg Proteinase K (Sigma) 
was added and incubated for 4 h at 56°C.  The suspension was centrifuged for 30 min at 
12,100 x g, 4°C.  The supernatant was transferred to a new 1.5 ml centrifuge tube and 
frozen at -80°C for 48 h, lyophilised overnight, and hydrolysed.  Hydrolysis was performed 
using 2M TFA (trifluoroacetic acid) in 10 mg of CPS, at 80°C for 4 h, centrifuged for 10 min 
at 12,100 x g, at room temperature.  The supernatant was filtered (0.22 µm), and the 
filtrate was used for GC-MS.  
Gas chromatography mass spectrometry (GC-MS) 
Aliquots (100 µl) of each hydrolysed sample were freeze-dried.  Derivatization and 
introduction of the samples was then performed by an autosampler (MPS-2XL) equipped 
with a heated agitator (Gerstel Mülheim an der Ruhr). Each sample was derivatized to its 
Meox-TMS derivatives through 1 h reaction with 10 µl of 40 mg/ml methoxyamine 
hydroxychloride solution in pyridine (Sigma-Aldrich, St Louis, MO, USA), followed by 2 h 
reaction with 20 µl of N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA) with 1% 
Trimethylchlorosilane (TMCS) (Machery-Nagel), both at 37oC under constant stirring at 
750 rpm. Derivatized samples (1 ul) were then injected in splitless mode at 250oC using 
helium as a carrier gas under a constant flow of 1 ml/min. Metabolites were separated on a 
Varian capillary column (Factor FOUR VF-5 ms: 0.25 mm, 0.25 µm, 30 m length with a 
10 m fused guard column) (Varian) installed on an Agilent 7890A gas chromatograph 
coupled with an Agilent 5975C MSD mass spectrometer (Agilent, Mulgrave, VIC, 
Australia). The initial temperature of the separation program was held for 1 min at 70oC, 
then increased to 325oC at a rate of 7oC /min and held for 3.5 min. The ion source, 
quadrupole and transfer line were set at 300oC, 150oC and 280oC respectively.  Glucose 
and galactose were detected in both total ion count mode (TIC) and in selected ion 
monitoring mode (SIM) for identification and quantification purposes respectively. 
Identification was achieved by matching the retention times and the fragmentation patterns 
to standards (Sigma-Aldrich, St Louis, MO, USA). Relative quantification was achieved by 
dividing the peak area of the characteristic ion of glucose to galactose with mass to charge 
(m/z) ratio of 319. 
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Growth curves for QMA0142, ΔcpsG and complemented ΔcpsG 
Starter cultures of bacterial isolates were prepared in THB grown overnight as above.  A 2 
%(v/v) inoculum was then used to inoculate fresh THB or terrific broth (Difco) with either D-
glucose or D-galactose (to 55mM from a 10% stock solution) added as a carbon source in 
a 96-well flat-bottomed plate (Greiner).  Growth was measured by measuring optical 
density at 600 nm, over a 12 h period at 28°C. Assays were performed in triplicate with 
independent starter cultures each time.   
Vaccine formulation and antibody production 
Killed bacterin vaccines were prepared by picking a single colony from QMA0142 and 
ΔcpsG grown overnight on blood agar and following established protocols (42). The 
vaccines were formulated as emulsions in Freund’s incomplete adjuvant delivered by 
intraperitoneal injection as described previously (42). Eight juvenile barramundi (Lates 
calcarifer) were vaccinated per treatment, including PBS/adjuvant emulsion controls. Blood 
was collected from euthanized (overdose of anaesthetic, Aqui-S) fish after 900 degree 
days (30 days at 30°C), by caudal venipuncture.  Blood was allowed to clot for 1 h at room 
temperature, then overnight at 4°C to ensure complete removal of fibrin and other clotting 
factors. Serum was collected by decanting the supernatant after centrifugation at 12,100 x 
g for 5 min and stored at -20°C until required. Animal use was approved by the UQ Animal 
Ethics Committee (AEC) for project SBS/060/10 “Protecting farmed barramundi from 
Streptococcal infection by vaccination”. 
Detection of CPS antigenic cross-reactivity by ELISA 
Serum collected from injected fish was used in whole cell and CPS extract ELISA following 
a modified protocol (42). Capsule extracts were prepared as described above, and high-
binding 96-well ELISA plates (Greiner) were coated with 2 µg CPS from each strain in 100 
µl carbonate bicarbonate buffer. 
Whole blood bactericidal and opsonisation assays 
Fresh blood was collected by caudal venipuncture from barramundi  (Lates calcarifer) 
euthanized by anaesthetic overdose. Blood bactericidal assays were performed essentially 
as described previously (43).  Bacteria were enumerated before and after incubation for 60 
min in blood by viable counts of 25 µl aliquots on TH agar plates in replicates of 6, 
following incubation overnight at 28°C.  For opsonisation, bacteria were incubated for 2 h 
in serum at a concentration previously determined by ELISA, then incubated with blood for 
60 min to determine survival. Blood for bactericidal assays was obtained by coordinated 
tissue sharing with UQ AEC approved project SBS/056/13 “Cellular immunity in fish: 
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Robust defence against infection or Achilles’ heel?” whereby euthanized fish had to be 
bled prior to recovery of monocytes from haematopoietic tissues (44). 
Transmission Electron Microscopy (TEM) 
Mid-exponential cultures (10 ml) of each strain were prepared by using overnight THB 
cultures as starter inocula (2% v/v) in fresh THB and incubating for ~5 h at 28°C with 
gentle agitation. Cells were washed in 70 mM sodium cacodylate buffer and immediately 
fixed on ice in glutaraldehyde diluted to 3.6% in 70 mM sodium cacodylate buffer for 1 h. 
Fixative was removed with 3 washes in cacodylate buffer and the cells were stained with 
ferritin (0.1 mg/L) in cacodylate buffer for 1 h on ice. Cells were washed 6 x in 70 mM 
cacodylate buffer then processed for TEM using standard dehydration and embedding 
processes. 
Statistical Analyses 
Data analyses were performed with Prism 6 (GraphPad Software, Inc.).  Growth curves 
were fitted using the Weibul equation and then compared by F-test. In vitro whole-blood 
opsonisation and bactericidal activity data were analysed by ANOVA followed by Tukey’s 
multiple comparison tests post hoc. ELISA data were analysed by two-way ANOVA to 
identify significant effect of vaccine and coating antigen. In all cases p = 0.05 was 
employed to define statistical significance. 
3.3 Results 
Phenotypic effects of cpsG deletion in S. iniae 
To further elucidate the roles of cpsG in CPS biosynthesis and serotype switching an 
isogenic knockout was prepared in the cpsG wild type strain of S. iniae QMA0142 isolated 
from barramundi in Northern Territory, Australia during a disease epizootic. Knockout of 
cpsG was confirmed by RT-PCR showing normal mid-log expression of cpsF, cpsG and 
cpsH in WT and rescue mutant, but no expression of cpsG in the knockout (Fig. 1).  
Moreover, similar expression of cpsH downstream of cpsG in the knockout and rescue 
mutants compared with the wild type parent suggested no polar effects of the in-frame 
allelic exchange in the operon (Fig. 1). Wild type isolates of S. iniae QMA0142 develop 
small umbonate translucent colonies on sheep blood agar overnight at 28°C whereas the 
cpsG mutant produced small white opaque colonies (Fig. 2A). Buoyant density of the cells 
was marginally affected by the cpsG mutation with cell suspensions becoming more 
diffuse in a Percoll separation compared to the parent (Fig. 2B). To investigate possible 
metabolic effects from the mutation, growth curves in liquid culture of the parental 
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QMA0142, cpsG mutant strain and complemented mutant were compared.  There were 
significant differences (p < 0.001, F-test) between growth curves for the cpsG mutant and 
the wild-type parent strain as the cpsG mutant grew more slowly in all three growth media 
tested (Fig. 2D-E). Growth was fully restored in the complemented mutant (Fig. 2D-E).  
 
 
Figure 2. Phenotypic traits of QMA0142 wild type cpsG ST1 and QMA0395 cpsG knockout prepared from 
parent QMA0142 by allelic exchange. A) Colony morphology on Columbia agar with 5% defibrinated sheep 
blood. B) Buoyant density in continuous Percoll gradients. C) Growth of wild type parent QMA0142, 
D) cpsG knockout mutant QMA0395 and E) complemented cpsG rescue QMA0395 in different growth 
media. 
 
 
Figure 3. Transmission electron micrographs showing cells of QMA0142 (WTST1), QMA0395 (cpsG KO) 
and QMA0502 in which has been rescued by knock-in of cpsG into QMA0395. Cells stained with 0.1% 
ferritin to label capsular polysaccharide. Scale bar in main picture = 1 µm. Insets show high magnification 
of single cells. 
 
There was an apparent ultrastructural change in CPS when stained with ferritin and 
observed by TEM (Fig. 3). The ferritin binding was less dense and less uniform across the 
cell surface in the knockout mutant compared to either the WT or the rescued mutant (Fig. 
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3 insets). However, there was variability in CPS cell coverage between cells within each 
culture when viewed under TEM at lower magnification, with some cells having no 
apparent attached capsule (Fig. 3). ST1 wild type and the rescued mutant exclusively 
exhibited complete surface coverage with CPS, which was viewed under TEM (Fig. 3). 
Deletion of cpsG increases levels of capsular glucose relative to galactose 
GC-MS was used to quantify glucose and galactose in CPS extracts from parental 
QMA0142, cpsG mutant and complemented mutant and wild type cpsG ST variants ST2 
and ST3. CPS from ΔcpsG had significantly increased glucose content compared to the 
wild type ST1, whereas the capsule purified from the complemented mutant contained 
levels of glucose similar to those of the WT (Fig. 4).  CPS from the ST3 variant contained a 
marginal increase in glucose relative to galactose compared with ST1, while CPS 
extracted from ST2 comprised the highest levels of glucose out of all the samples tested 
(Fig. 4). To determine whether the variation in glucose/galactose ratio in CPS in the 
different sequence types could be explained by the insertion deletion mutations, the amino 
acid sequences were analysed for effect on epimerase activity in Provean. Provean 
predicted a deleterious effect of the deletion of LSK in ST2 compared to ST1 (score -
14.556, Fig 5), and also insertion of an additional LSK in ST3 relative to ST1 (score – 
9.803, Fig 5).  
 
 
Figure 4. Glucose: Galactose ratio in purified hydrolyzed CPS determined by GC-MS. Differing letters 
indicate statistically significant differences (Unpaired t-test p<0.05) 
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Figure 5. Amino acid sequences of ST1, ST2 and ST3 variants of cpsG from S. iniae showing active sites, 
NAD binding sites and substrate binding site predicted in silico by conserved domain database search. 
Insertion and deletion mutations in the variants are indicated by shaded boxes. Box inset indicates molecular 
weights, pI and effect of insertion and deletion mutations on enzyme activity predicted by Provean (39). 
Role of cpsG in immunogenicity and cross-opsonisation in fish 
To determine how changes in cpsG effect antibody recognition, juvenile barramundi were 
immunised with formalin killed bacterins prepared from WT ST1 parental strain QMAO142 
and the cpsG deletion mutant, and a virulent ST2 variant, QMA0248, that has been shown 
to be virulent in barramundi and illicit protective immunity by vaccination in barramundi 
(42). In whole cell ELISA, neither QMA0142 nor ΔcpsG elicited a strong antibody response 
compared to adjuvant only controls (Fig. 6A). This was not due to any problem with the 
fish as the positive control vaccine against QMA0248 elicited a significant specific 
homologous antibody response compared to the adjuvant control (Fig. 6A). As S. iniae M-
protein can bind host immunoglobulin in a non-immune manner via the Fc portion of the 
IgM molecule (45, 46) potentially masking specific immune binding in whole cell reactions, 
a second ELISA in which purified CPS was employed as the coating antigen was 
performed. This revealed that there was specific antibody response against CPS, but there 
was no significant difference between sera from fish injected with the knockout compared 
with sera from fish injected with the wild type CPS (Fig. 6B). To determine differences in 
the ability of the respective antisera to opsonise S. iniae, the wild type, ΔcpsG, and 
complemented mutant were pre-incubated with normal serum (control), or antiserum 
against wild type QMA0142 (ST1) or QMA0395 (ΔcpsG), prior to inoculation into fresh 
whole blood from barramundi. Non-opsonised cells grew significantly during the 1 h 
incubation, increasing cell numbers by more than 50% for all strains except ΔcpsG where 
the increase in cell number was less than 10% over 1 h. Opsonisation with anti-QMA0142 
antibody resulted in significant killing of QMA0142 (Fig. 6C).  Growth of the ΔcpsG mutant 
was not significantly reduced by either anti-QMA0142 or anti-ΔcpsG antibody in the whole-
blood killing assay.  
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Figure 6. Immunoreactivity of wild type and cpsG knockout mutant S. iniae by whole cell (A) and purified 
CPS (B) ELISA. C) Opsonisation by barramundi antibodies in whole barramundi blood bactericidal assay. 
Differences between treatments with differing letters are significant (ANOVA with post-hoc Tukey’s multiple 
comparison tests p<0.05). 
 
3.4 Discussion 
The capsular polysaccharide is a major virulence factor in S. iniae, and CPS-deficient 
knockouts are attenuated (43). Nonetheless, wild-type CPS deficient isolates have been 
identified in naturally infected farmed fish, albeit causing markedly different pathology and 
greatly reduced morbidity (14). CPS promotes virulence by enhancing survival in fish 
blood possibly by inhibition of phagocytosis (43). However, there is a trade-off as CPS is a 
major antigen recognised by the fish adaptive immune system (47), consequently 
vaccination with formalin killed bacterins is highly protective against homologous CPS-
types (42, 48, 49). Introduction of vaccination against S. iniae in several aquaculture 
species has resulted in relatively rapid emergence of novel capsular serotypes and 
consequent vaccine failure (12-14). There is no defined serological typing system for S 
iniae but vaccine escapes are antigenically distinct (12), have differing exopolysaccharides 
(13) and are correlated with coding mutations in a limited subset of the 20 genes of the 
cps operon (14). In Australian barramundi farms, killed monovalent or polyvalent 
autogenous vaccines are used that include the strains isolated from the most recent 
infections (14). Here, insertion/deletion mutations in cpsG occur most frequently in vaccine 
escapes.  
The cpsG gene encodes a putative UDP-galactose-4-epimerase (24) and epimerase 
activity is supported here as the capsular polysaccharide of our cpsG knockout mutant 
comprised substantially more glucose compared to galactose than the wild type parent 
strain, suggesting that epimerase activity is favoured in the glucose to galactose direction. 
Insertion/deletion mutations in the substrate binding site region gene found in naturally 
occurring vaccine escape strains also resulted in changes in the glucose/galactose ratio of 
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the capsule by GC-MS. This was consistent with in silico predictions of the effects of these 
mutations using Provean, in which both the insertion (ST3) and the deletion (ST2) 
mutations resulted in predicted deleterious effect on activity. The deletion had a greater 
effect than the insertion (Fig. 4); resulting in a 50% and 100% increase in glucose relative 
to galactose in the variant CPS compared ST1 CPS (Fig. 3).  
Higher glucose in the capsule marginally impacted buoyant density in cells, evidenced in 
Percoll gradients and this correlated with reduced ferritin binding observed in TEM. 
However, there was considerable variability in electron dense surface structure revealed 
by ferritin within the same culture. This may reflect differing capsular expression levels 
between individual cells as capsular polysaccharide biosynthesis has been shown to be 
phase variable in other species such as S. pneumoniae and N. meningitides (50, 51) 
There was a significant affect on growth in blood from naive barramundi: S. iniae cpsG 
ST1 wild type strain QMA0142 increased 50% in blood after 1 h. In contrast, the cpsG 
mutant did not proliferate in blood during the same period. Similar differences in 
proliferation/killing determined in ex vivo blood survival assays have been reported 
between CPS types I, II and IV of S. pneumoniae (17).  It is possible that the differing 
capsular composition in several Streptococcus species increases visibility to lectin and/or 
neutrophil detection thereby reducing the ability to proliferate in whole blood. However it is 
more likely that the effect detected in S. iniae in this study is metabolic, as growth in Todd-
Hewitt broth and terrific broth with either glucose or galactose as the preferred carbon 
source was also impeded in the cpsG knockout compared to wild type, and was fully 
restored in the complemented mutant. This suggests that this epimerase, in spite of its 
membrane location, may be co-opted into general carbon metabolic pathways in S. iniae, 
consistent with efficient use of genetic resources by bacteria and continued evolution by 
genome reduction. Indeed, epimerase from the Leloir pathway has been implicated in CPS 
production in some strains of S. thermophilus, perhaps through biosynthesis of essential 
precursors as epimerase activity is higher in strains with no galactose in the CPS (52). 
Ongoing analyses of wild type and cpsG mutant isolates may better inform how this 
epimerase may be used in energy metabolism.  
When measured by whole cell ELISA, antibody response was low against both the S. iniae 
wild type and the cpsG mutant in barramundi. Fish yield a much lower detectable antibody 
response to vaccination, in terms of titre, than mammals. This reflects the generally lower 
affinity and avidity of teleost immunoglobulins (predominantly tetrameric IgM in serum, with 
some monomeric IgT in some species) and the lack of immunoglobulin class-switching 
	55	
(53). The high background in the whole cell ELISA indicated by high optical density 
detected with sera from adjuvant only controls is likely due to non-immune binding of the 
serum immunoglobulins by the SiMA M-like proteins in S. iniae (46). This is partially 
corroborated by the decrease in background and increase in resolution between 
vaccinated and non-vaccinated fish detected when CPS was employed as the coating 
ELISA antigen. It is also possible to increase resolution in whole cell ELISA with S. iniae 
by using 2% normal goat serum as a blocking agent instead of BSA (42). Nevertheless, 
there was antigenic cross-reactivity between the knockout and wild-type isolate in the anti-
CPS ELISA, but this did not translate to cross-opsonisation as the heterologous sera failed 
to opsonise the bacteria in whole blood. Cross-reactivity but low cross-opsonisation has 
also been reported in patients vaccinated against S. pneumoniae (54, 55) and has been 
attributed to low avidity of IgG after class-switching (55). However, it is difficult to draw 
parallels as the B-cell response in fish is different to that in humans and class switching is 
thought not to occur, although responses are considered very complex and are not yet 
fully understood (53). Nevertheless, opsonising antibody is likely to explain the very high 
protection reported for killed bacterins against S. iniae in fish (42). Lack of cross-
opsonisation between different cps types in S. iniae is the probable explanation for 
occasional vaccine escape recorded in fish farms (12, 14).  
3.5 Conclusions  
We have shown here that functional mutations in cpsG encoding an epimerase in the 
capsular operon of S. iniae result in altered CPS composition and this in turn results in 
poor cross-opsonisation that might explain some of the historic vaccination failure on fish 
farms in Australia. The activity of epimerases in switching monosaccharide isomers and 
thereby affecting structural phenotype of polysaccharides downstream in the biosynthesis 
pathway makes them likely candidates for strong selection by protective host immunity 
directed against the polysaccharide structure. These findings have implications for the 
understanding of vaccine escape in other pathogens of humans and animals where 
epimerases are critical key steps in the biosynthesis of major serotype-specific antigenic 
polysaccharides including capsule and lipopolysaccharide. Further work is required to 
determine whether these changes in the cps operon arise spontaneously by mutation, are 
selected in response to stress imposed by the immune host, are acquired horizontally, or 
are in fact a result of serotype replacement from a pool of extant strains in the farm 
environment that have comparatively increased fitness in the presence of immunised fish.   
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4. Conclusions & Discussion 
The ability of bacteria to evolve between or during infection in response to clinical 
intervention requires in-depth understanding of the pathogen and its interactions within the 
host (1, 2).  The molecular genetics of host pathogen interactions are shedding light on 
metabolic pathways that contribute to pathogen survival and the vast datasets provided by 
genome re-sequencing are highlighting evolution of potential vaccine targets during use 
(3).  Epitope evolution and antigenicity is a major concern for developers of vaccine 
candidates (4-6), including streptococcal CPS designed vaccines (7, 8).    
The objective of the work described in this was to better understand molecular evolution of 
the capsular operon, the role of mutation in specific capsule biosynthesis genes, and the 
affect of such mutation on capsular antigenicity of Streptococcus iniae.  To address this 
objective three aims were employed: 
1) Identify re-emerging strains of S. iniae and identify genetic changes using 
large scale screening of capsular genes 
2). Use allelic replacement to knockout genes in the capsular operon of S. iniae, 
and elucidate phenotypes with a defined genetic background 
3) Raise antibodies in barramundi and use ELISA and bacterial killing assays to 
determine antigenic properties of mutant strains 
Chapter 2 addressed the first aim in an investigation of re-emerging strains of S. iniae in 
previously vaccinated barramundi (Lates calcarifer) on fish farms in Australia.  The 
capsular operon of 39 strains was genetically screened, identifying several mutations, but 
only in a limited repertoire of genes in the operon.  Of the 21 kb region screened, 
mutations occurred within what is thought to be the biosynthesis region of the operon 
(cpsY, cpsD, cpsE, cpsG & cpsH).  A unique amino acid arrangement was found in some 
strains of cpsG where LSK (leucine, serine, lysine) was deleted in strain type 2, and the 
same amino acid sequence duplicated in strain type 3.  Amino acid changes can lead to 
antigenic variation and antimicrobial resistance in a diverse range of bacteria (9, 10).  
Since cpsG is postulated to be an epimerase, a critical enzyme for interchanging glucose 
and galactose, we hypothesized that these amino acid changes would ultimately affect the 
antigenicity of the CPS.  Additionally, eight strain types were identified for cpsE composed 
of non-synonymous mutations and a frame-shift mutation in one of the re-emerging 
strains. Subsequent histology of the infected barramundi revealed S. iniae in the bone and 
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acapsular forms. The mutations in the biosynthesis genes and new pathology discovered 
in S. iniae provided the foundation for the rest of this thesis.   
Chapter 3 addressed aims 2 and 3 using microbiological and molecular approaches.   
With specific biosynthesis genes being identified in Chapter 2, as well as mutations within 
those genes, experiments were undertaken to understand how these identified genes 
function in the capsular operon.  cpsG, encoding a UDP-glucose 4’-epimerase, was 
genetically knocked-out to ascertain effects on capsule production, and ultimately how fish 
host immune cells would perceive modified S. iniae.  Since cpsG is thought to regulate the 
glucose:galactose ratio for capsule production, we hypothesised that by deleting the cpsG 
gene there would be a measureable difference in S. iniae capsular production and the 
immune responses of fish. The gene was successfully knocked-out and found to act on 
the glucose:galactose ratio in capsule production.  Immunoassays revealed that the 
mutant did not grow well in whole blood and cross-opsonisation was less than for other 
strains tested.  Additionally, in an ELISA assay, detection by barramundi antibodies was 
minimal and no noticeable difference was observed when comparing the mutant to the 
WT.  We concluded that the increase in glucose in the mutant might be allowing the 
mutant to go undetected, and that the amino acid mutations in cpsG (as in those found in 
chapter 2) are affecting the glucose:galactose ratio and could be contributing to re-
emergence in the field.   
Molecular biology techniques have greatly improved the current understanding of genetics 
and virulence of streptococci.  Employing genetic techniques such as allelic exchange are 
being used to provide insight on gene function, virulence, and antigenicity (9, 11, 12).  
Previous research has focused on biosynthesis genes in the CPS operon of several 
pathogenic bacteria, investigating function and contributing to better vaccine design (13-
16). The majority of these studies highlight the contribution to virulence or lack thereof for 
bacterial CPS biosynthesis genes using various animal models including zebra fish (Danio 
rerio) and mice (17, 18). In order to appropriately assess virulence it is necessary to 
challenge a model organism and look for attenuated or accelerated potential of the 
pathogen in question.  Another approach before considering virulence testing would be to 
evaluate mutational effects on antigenicity.  This should be considered in cases where the 
pathogen in question has re-emerged after a vaccine program (19).  Many vaccines are 
frequently reformulated due to evolution of pathogens after clinical intervention (4, 7, 20, 
21).  Investigating these highly antigenic targets is critical for vaccine design and for 
understanding evolution of pathogenic bacteria (22).   
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This thesis was conceived following the collection of data from re-emerging S. iniae strains 
from multiple barramundi fish farms around Australia.  Re-emerging S. iniae strains not 
only occurred in Australia, but also in Israel after vaccination (19), highlighting the need to 
understand effects of clinical intervention on fish farms.  Previous research on S. iniae 
infections in fish has shown various pathology and virulence mechanisms (23-25), yet 
understanding how re-infection occurs remains less well known. 
Since several Australian fish farms were experiencing massive barramundi losses due to 
infections with S. iniae it was imperative to investigate the main vaccine target in S. iniae, 
the CPS.  We undertook this task by performing a genetic screen of the approximately 21 
genes present in the CPS operon. Other groups have performed similar experiments with 
the pneumococci to investigate serotype changes (13). Similarly, we found several 
mutations in key biosynthesis genes.   
Several genes have been thoroughly described in the CPS operon of S.iniae, including 
cpsD (autophosphorylating protein tyrosine kinase) and cpsY (transcriptional regulator), 
providing key information on how the bacteria regulate CPS production (14, 16), but we 
found these genes to be highly conserved amongst pre and post vaccination isolates and 
therefore unlikely to contribute to serotype shift in these cases.  However, no previous 
studies had investigated the sugar-modifying components of the operon that are most 
likely to have an antigenic role such as cpsG in S. iniae.  Given the unique situation of 
having an essentially “closed system” through the cyclical autogenous vaccination 
programs, I was able to provide insight on epitope evolution after vaccination. This 
information paved the way for investigating the other mutated genes identified in the 
screen, with particular focus on cpsE, which revealed a further eight distinct strain types 
due to non-synonymous mutations.  
A glycosyltransferase (GT), cpsE, is thought to be critical in the capsule biosynthesis 
process, specifically for building the polysaccharide (26).  The utilization of GT’s varies 
between organisms, but in Gram-positive and Gram-negative bacteria they are located in 
the ABC transport pathway (Gram negative) and Wzy and synthase dependent pathways 
(Gram positive) (26).  These pathways are responsible for synthesis and export of 
polysaccharide to the cell surface to produce an extracellular capsule or cell wall structure 
that assists the bacterium in evading the host’s immune system (27).   Genes that encode 
GT’s in bacteria such as S. iniae and Streptococcus pneumoniae are located in the CPS 
operon (15, 28).  Mutations in GT’s have led to capsule variability and altered antigenicity 
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in S. pneumoniae (29).  GT mutations also impact Gram-negative bacteria: in Salmonella 
enterica and Salmonella bongori, heterogeneity of the O-antigen of the lipopolysaccharide 
(LPS) occurs via genetic recombination events in glucosyltransferase (same family as 
glycosyltransferases) genes that are located outside of the LPS operon (30).   
In Gram-positive Streptococcus thermophilus, the GT’s are grouped together (epsE, epsF, 
epsG and epsI), with each one contributing to the production of the exopolysaccharide 
(31).  Similarly, in the CPS operon of S. iniae, a group of putative GT’s (cpsE, cpsF, cpsK, 
and cpsL) is located, yet it is unknown if these function together to construct the 
polysaccharide as in other streptococcal species (32).  What we do know is that the 
genetic screen described in Chapter 2 revealed no mutations in the GT genes: cpsF, cpsK 
or cpsL, with mutations only identified in cpsE (8).  Additionally, an unusual pathology was 
observed in one strain, where cpsE had a frameshift mutation resulting in an early stop 
codon and multiple downstream genes were deleted (including the other GT’s).  Buoyant 
density assays showed the strain was acapsular, and histology revealed the bacterium 
residing in the bone of the fish in contrast to infection of the blood, meninges and choroid 
rete that is normally associated with S. iniae pathology.  None of the other strains obtained 
displayed this unusual pathology, except this strain type missing multiple biosynthesis 
genes from the CPS operon.  One potential explanation for multiple synomymous and 
non-synonymous mutations in cpsE is that GTs downstream in the operon can effectively 
fulfil the same role. In contrast, when these subsequent highly conserved GT genes are 
missing CPS biosynthesis is effectively inactive. This is in keeping with a hypothesis that 
that the genome of S. iniae is undergoing reductive evolution, and that cpsE may 
eventually be lost from genome. Evolution in response to changing environmental niches 
has been documented in many pathogenic bacteria and genome reduction has been 
previously described (33, 34).  Understanding the function of cpsE and the other GT’s in S. 
iniae will help elucidate which genes are absolutely required for polysaccharide synthesis.   
The findings presented here shed light on two genes in the CPS operon of S. iniae and 
their role in capsule biosynthesis.   The effects on antigenicity were determined, albeit they 
did not alter the capsule in such a way that would make these mutant forms vaccine 
candidates. Instead, this work provided insight into the function of these CPS genes and 
their contribution to immune evasion.  Multiple spontaneous mutations occurring in the 
CPS operon after vaccination highlight the capacity of S. iniae to respond evolutionarily to 
specific vaccines, and ultimately switch the serotype.  Autogenous vaccines on Australian 
fish farms are driving epitope variation, and there is a continuing need to further 
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understand and monitor the genes contributing to antigenic variation in S. iniae. Moreover, 
the search for conserved essential surface or secreted factors to target in vaccines is more 
important than ever. With the rapid advance of bacterial genomics accompanied by greatly 
reduced cost, identifying such candidates is becoming both feasible and affordable for 
lower economic value species such as fish. 
Future Directions 
Recent advances in genomics have shed light on our understanding of pathogen dispersal 
and evolution. For instance, a recent study on outbreaks of Escherichia coli ST131, 
extrapolated when virulence factors were acquired and the overall effect on global 
dissemination (35).  Additionally, virulence evolution has been elaborately characterised 
for entire bacterial genera such as Yersinia (36).  Since the genome was recently 
sequenced for S. iniae (32), it is now possible to explore using these methods to 
investigate metabolic pathways of CPS biosynthesis genes in greater detail.   
At the outset of this project in 2012, large-scale bacterial genomics was beginning to 
advance but was still expensive, and out of reach for research in the field of fish diseases. 
Over the last 4 years the costs have fallen dramatically bringing large-scale whole genome 
within reach for investigating evolution and dispersal of fish pathogens. For example, 
genomics revealed that the salmonid pathogen Renibacterium salmoninarum has evolved 
incredibly slowly as it has been dispersed through Northern Europe and North America 
(37). A small-scale genomic study on terrestrial and aquatic strains of Streptococcus 
agalactiae also revealed slow evolution amongst aquatic strains (38).  Not only are 
researchers identifying evolutionary time scales, but they are also finding mechanisms for 
adapting to various environments.  In Aeromonas salmonicida, a fish pathogen, Vincent 
and colleagues (2016) discovered a strain that was evolving from a mesophilic 
environment to a psychrophilic lifestyle. Their comparison of A. salmonicida strains with 
the rest of Aeromonas genus species found high amounts of diversity in A. salmonicida in 
which they postulated was due to insertion sequences (39).  The application of genomics 
coupled to evolutionary analysis can greatly accelerate vaccine design and improvement 
through reverse vaccinology (3, 40).  This approach has been successfully implemented 
targeting slowly evolving protein antigens in Neisseria meningitidis (serogroup B) found in 
humans (41).  Reverse vaccinology can be used now to cost-effectively design and 
steward fish vaccines through the filed lifetimes, which will be critical as aquaculture grows 
to supply the world with sustainable fish. 
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S1. Table of S. iniae isolates used in this study, including country/ state and site of 
origin (where known), isolation date, and ST of variable genes from the capsular 
operon (after Barnes, 2010)(1). 
QLD, Queensland, NSW, New South Wales, NT, Northern Territory. Separate farm sites are indicated by 
differing numbers in parentheses. Month and year of isolation are given where known. X indicates deleted 
gene. *frameshift mutation resulting in early stop codon  
Strain cpsY cpsC cpsD cpsE cpsG cpsH State (site) Previous 
Designation 
Date 
Type Strain  
QMA0140 1 1 1 1 1 1 USA  ATCC29178 1970 
Australian Isolates (by state)  
QMA0072 1 1 3 3A 1 1 QLD(1) 95-40786 1995 
QMA0076 1 1 3 4 1 1 QLD(2)  98-49835 1998 
QMA0078 1 1 3 3 1 1 QLD(3) 1-41291 2001 
QMA0165 1 1 3 3A 1 2 QLD(4) 06-40593 2006 
QMA0170 1 1 3 3A 1 2 QLD(4) 06-43734 2006 
QMA0164 1 1 3 3A 1 2 QLD(5) 06-40191 2006 
QMA0216 1 1 3 7   QLD(6) E 2007 
QMA0218 1 1 3 3A 1 2 QLD(4) G 2007 
QMA0155 1 1 3 3 2 1 NSW(1) 1 12/2005 
QMA0220 1 1 3 3 2 1 NSW(1) I 08/2006 
QMA0250 1 1 3 3 2 1 NSW(1) I6 11/2007 
QMA0251 1 1 3 3 2 1 NSW(1) I7 06/2008 
QMA0252 1 1 3 3 2 1 NSW(1) I8 06/2008 
QMA0233 1 1 1 5A* X X NSW(1) 1 11/2008 
QMA0253 1 1 1 5A* X X NSW(1) I9 01/2009 
QMA0254 1 1 1 5A* X X NSW(1) I10 01/2009 
QMA0236 1 1 1 5A* X X NSW(1) 4 03/2009 
QMA0191  2 1 3 3 1 1 NT(1) 05/0409 04/2005 
QMA0142 2 1 3 3 1 1 NT(1) 05/0430-D 07/2005 
QMA0150 2 1 3 3 1 1 NT(1) 05/1151-D 08/2005 
QMA0153 2 1 3 3 1 1 NT(1) 05/1383-D 09/2005 
QMA0177 2 1 3 3 3 1 NT(1) 06/0784-G 07/2006 
QMA0158 1 1 3 6* 2 1 SA(1) 4 02/2006 
QMA0159 1 1 3 3 2 1 SA(2) 5 02/2006 
QMA0160 1 1 3 3 1 1 SA(3) 6 12/1999 
QMA0173 1 1 3 3 2 1 SA(?) AVM-2958 2006 
QMA0243 1 1 3 3 2 1 SA(3) R1 05/2006 
QMA0244 1 1 3 3 2 1 SA(3) R2 10/2008 
QMA0245 1 1 3 3 2 1 SA(3) R3 10/2008 
QMA0246 1 1 3 3 2 1 SA(3) R4 03/2009 
QMA0247 1 1 3 3 2 1 SA(3) R5 03/2009 
QMA0248 1 1 3 3 2 1 SA(3) R6 03/2009 
QMA0249 1 1 1 5* X X SA(3) R7 05/2009 
QMA0083 1 1 3 3 2 1 WA(1) AS-04-0006#1 2004 
International Isolates  
QMA0186 1 1 2 2 X 1 Israel KFP404  
QMA0188 1 1 3A 2 X 1 Israel KFP173  
QMA0189 1 1 4 8 X 1 Réunion Is. 21-96 (2) 1996 
QMA0190 1 1 1 5* 1 1 Thailand CII.5b-88 1988 
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S2. Primers and annealing temperatures for amplification of variable cps genes in 
the capsular operon of S. iniae (after Barnes, 2010)(1). 
Forward 
primer 
Reverse 
primer 
Gene/s 
targeted 
Annealing 
temperature (ºC) 
Expected product 
size (kb) 
HKi F CPSA R cpsY 65 3.0 
CPSB F CPSD R cpsB-D 55 2.2 
CPSE F CPSE R cpsE 58 1.8 
CPSF F CPSH R cpsF-H 64 2.5 
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S3. Oligonucleotide primer sequences used for sequencing capsular operon genes 
from templates generated by long-range PCR (after Barnes, 2010)(1). 
 
Primer	 Sequence	5’-3’	
CPS Y F  TTATATTTCCTTTTTTTGTGTCAATTTGA 
CPS Y R  ATGAGAATACAACAATTACATTACA 
CPS A F  TGATTGGAGTTAAAAAGTAATG 
CPS A R  ATCGCATAGGATGGCAATTCA 
CPS B F  CAGTAATGGGAGGAAAGTAAATG 
CPS C R  TTGTGACATCCTTAACCTC 
CPS D R  TCACTTTCTGGAATGTTTTTTAC 
CPS E F  ATGAAAAGAAGTCAAAAAAGAGTAATC 
CPS E R  TTACTCCTGTTTAGCGTCATTTA 
CPS F F  ATGTATCCTTATATTAAACGAC 
CPS F R  TCACTTCTCCTTATTTTGCTCTG 
CPS G F  ATGAAAAAAGTACTTATTACAGGTGC 
CPS G R  CTATATTTTTTCATTGTTTCTTTCC 
CPS H F  ATGAAAAAATATAGTAGAAGTGTG 
CPS I R  AATCTCCTATTTTTTCCCACAT 
CPS J F  ATGAAAATACTTGTGACAGGTG 
CPS K F  ATGATAACTGTTTGTATGGCAAC 
CPS K R  TTACCATTTTTTATTTTTCCTTTTTGTTT 
CPS L F  ATGAAAGTAGCGTTTTATTTAGAT 
CPS L F RC  ATCTAAATAAAACGCTACTTTCAT 
CPS L R  GTGTTCATCTGGTATTTTTTATTAA 
CPS L R RC  TTAATAAAAAATACCAGATGAACAC 
ORF276 F  ATGAGGGTATCTATAAAAAGTATAA 
ORF193 F  ATGTTGCTGTTACTGACATTAACATT 
ORF193 F RC  AATGTTAATGTCAGTAACAGCAACAT 
ORF193 i R  AAACTAGAACCTGAAAGAAAAATACC 
ORF151 R  TCATAGATACTCCTTTTCCTGTT 
CPS M F RC  AATTCAATTTTATACTGTTTTTTTTCAT 
CPS M R  ATATAAGAACTAAAAAATTCAAGTCAAATTAA 
CPS N F  ATGAAAAAAATAGCAGTTGCTGG 
CPS N R  TTAATCCCGGCCGAAAAGGT 
ORF183 R  TTAGACTTCCTGAGCTGCGAA 	 	
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